[go: up one dir, main page]

WO2004097049A1 - Oligoribonucleotides et ribonucleases de clivage d'arn - Google Patents

Oligoribonucleotides et ribonucleases de clivage d'arn Download PDF

Info

Publication number
WO2004097049A1
WO2004097049A1 PCT/US2003/009808 US0309808W WO2004097049A1 WO 2004097049 A1 WO2004097049 A1 WO 2004097049A1 US 0309808 W US0309808 W US 0309808W WO 2004097049 A1 WO2004097049 A1 WO 2004097049A1
Authority
WO
WIPO (PCT)
Prior art keywords
rna
target rna
compound
consecutive
strands
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/009808
Other languages
English (en)
Inventor
Stanley T. Crooke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Priority to AU2003220608A priority Critical patent/AU2003220608A1/en
Priority to EP03716922A priority patent/EP1611249A4/fr
Priority to PCT/US2003/009808 priority patent/WO2004097049A1/fr
Publication of WO2004097049A1 publication Critical patent/WO2004097049A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/311—Phosphotriesters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/313—Phosphorodithioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/316—Phosphonothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Definitions

  • This invention is directed to the synthesis and use of oligomeric compounds, including oligoribonucleotides and oligoribonucleosides, useful for strand cleavage of target RNA strands.
  • Further included in the invention are chimeric oligoribonucleotides and oligoribonucleosides having mixed backbones, either phosphate or non-phosphate.
  • RNA molecules are also included in the invention.
  • mammalian ribonucleases i.e., enzymes that degrade RNA.
  • a ribonuclease is referred to herein as a dsRNase, wherein "ds” indicates the RNase's specificity for certain double-stranded RNA substrates.
  • oligoribonucleotides, oligoribonucleosides, ribonucleases and ribonuclease substrates of the invention are useful for therapeutics, diagnostics and as research reagents.
  • Oligonucleotides are known to hybridize to single-stranded DNA or RNA molecules. Hybridization is the sequence-specific base pair hydrogen bonding of nucleobases of the oligonucleotides to nucleobases of target DNA or RNA. Such nucleobase pairs are said to be complementary to one another.
  • oligonucleotides The complementarity of oligonucleotides has been used for inhibition of a number of cellular targets. Such complementary oligonucleotides are commonly described as being antisense oligonucleotides. Various reviews describing the results of these studies have been published including Progress In Antisense Oligonucleotide Therapeutics, Crooke, S.T. and Bennett, C.F., Annu . Rev. Pharmacol . Toxicol . , 1996, 36, 107-129. These oligonucleotides have proven to be very powerful research tools and diagnostic agents. Further, certain oligonucleotides that have been shown to be efficacious are currently in human clinical trials.
  • Antisense oligodeoxynucleotides are believed to cause a reduction in target RNA levels principally through the action of RNase H, an endonuclease that cleaves the RNA strand of DNA:RNA duplexes.
  • RNase H an endonuclease that cleaves the RNA strand of DNA:RNA duplexes.
  • This enzyme thought to play a role in DNA replication, has been shown to be capable of cleaving the RNA component of the DNA:RNA duplexes in cell free systems as well as in Xenopus oocytes.
  • Rnase H is very sensitive to structural alterations in antisense oligonucleotides.
  • DNA oligonucleotides having both unmodified phosphodiester internucleoside linkages and modified phosphorothioate internucleoside linkages are substrates for cellular RNase H.
  • Patent 5,013,830 discloses mixed oligomers comprising an RNA oligomer, or a derivative thereof, conjugated to a DNA oligomer via a phosphodiester linkage.
  • the RNA oligomers also bear 2'- O-alkyl substituents.
  • the oligomers are susceptible to nuclease cleavage.
  • European Patent application 339,842 published November 2, 1989, discloses 2 ' -O-substituted phosphorothioate oligonucleotides, including 2 ' -O- methylribooligonucleotide phosphorothioate derivatives.
  • the above-mentioned application also discloses 2 ' -O- methyl phosphodiester oligonucleotides which lack nuclease resistance.
  • mixed phosphate backbone oligonucleotides which include an internal portion of deoxynucleotides linked by phosphodiester linkages, and flanked on each side by a portion of modified DNA or RNA sequences.
  • the flanking sequences include methyl phosphonate, phosphoromorpholidate, phosphoropiperazidate . or phosphoramidate linkages.
  • RNA:DNA probes targeted to DNA are labeled and are used in a system that includes RNase H.
  • the RNase H enzyme cleaves those probes that bind to DNA targets.
  • the probes can include modified phosphate groups. Mentioned are phosphotriester, hydrogen phosphonates, alkyl or aryl phosphonates, alkyl or aryl phosphoramidates, phosphorothioates or phosphoroselenates .
  • RNA I-RNA II hybrid of the ColEl plasmid see Haeuptle, M.T., Frank, R. , and Dobberstein, B., Nucleic Acids Res . 1986, 14 , 1427, Knecht, D., Cell Motil . Cytoskel . , 1989, 14 , 92-102; and Maniak, M. , and Nellen, W. , Nucleic Acids Res . , 1990, 18, 5375-5380; OOP-cII RNA regulation in bacteriophage Lambda, see Krinke, L., and Wulff, D.L. (1990) Genes Dev.
  • RNA:RNA duplexes formed have been shown to be substrates for regulated degradation by the endoribonuclease RNase III. Duplex dependent degradation has also been observed in the archaebacterium, Halobacterium salinarium, where the antisense transcript reduces expression of the early (Tl) transcript of the phage gene phiH, see Stolt, P., and Zillig, W., Mol . Microbiol . , 1993, 7, 875-882.
  • RNase III is the double stranded endoribonuclease (dsRNase) activity responsible for the degradation of some antisense : sense RNA duplexes.
  • dsRNase double stranded endoribonuclease
  • RNase III also plays an important role in mRNA processing and in the processing of rRNA precursors into 16S, 23S and 5S ribosomal RNAs, see Dunn, J.J. and Studier, F.W. J “ . Mol . Biol . , 1975, 99, 487.
  • a yeast gene RNT1 has recently been cloned that codes for a protein that has homology to E.coli RNase III and shows dsRNase activity in ribosomal RNA processing, see Elela, S.A., Igel, H. and Ares, M. Cell , 1996, 85, 115-124.
  • oligomeric compounds formed from a linear sequence of linked ribonucleoside subunits that are specifically hybridizable to a preselected RNA target.
  • the oligomeric compounds have at least a first segment and a second segment .
  • the first segment incorporates at least one ribonucleoside subunit that is' modified to improve at least one of its pharmacokinetic properties, its binding characteristics to target RNA or to modify its charge.
  • the second segment includes at least four consecutive ribofuranosyl nucleoside subunits.
  • the subunits of the oligomeric compounds are connected together in a linear sequence by internucleoside linkages that are stabilized from degradation as compared to phosphodiester linkages.
  • the compounds will include a third segment having properties corresponding to the properties of the first segment. It is preferred to position the second segment between the first and third segments such that they form a continuous, linear sequences of linked nucleoside units.
  • the number of such linked nucleoside subunits will range from about eight to about fifty with a more preferred range being from about twelve to about thirty linked nucleoside subunits .
  • Modification of pharmacokinetic properties includes any one or more of the modification of binding, absorption, distribution or clearance properties of the compound.
  • Modification of binding characteristics includes modification of the affinity or specificity of said compound to its target RNA.
  • Modification of the charge of said compound includes modifying the net charge of the compound as compared to an unmodified compound. Normally modification of charge will decrease the overall net negative charge of a phosphorus linked oligomeric compound to provide the compound with less negative charge, a neutral charge or a net positive charge .
  • oligomeric compounds formed from linear sequences of linked ribonucleoside subunits that are specifically hybridizable to a preselected RNA target.
  • the oligomeric compounds have at least a first segment and a second segment .
  • the first segment incorporates at least one ribonucleoside subunit that is functionalized to provide greater affinity to the target RNA.
  • the second segment includes at least four ribofuranosyl nucleoside subunits.
  • the subunits of the oligomeric compounds are connected together in a linear sequence by internucleoside linkages that are modified to stabilize the linkages from degradation as compared to phosphodiester linkages.
  • the first or first and third segments of oligomeric compounds are formed of nucleoside subunits that include 2 ' -substituent groups thereon.
  • the 2 ' -substituent group includes fluoro, C ⁇ -C 20 alkoxy, C ⁇ C 9 aminoalkoxy, allyloxy, imidazolylalkoxy and polyethylene glycol .
  • Preferred alkoxy substituents include methoxy, ethoxy and propoxy.
  • a preferred aminoalkoxy substituent is aminopropoxy.
  • a preferred imidazolylalkoxy substituent is imidazolylpropoxy.
  • a preferred polyethylene glycol substituent is -O-ethyl-O-methyl, i.e., methoxyethoxy or -0-CH 2 -CH 2 -0-CH 3 .
  • the oligomeric compounds are formed of nucleoside subunits that are modified by including certain selected nucleobases thereon.
  • the selected nucleobases include 2,6- diaminopurine, N2-alkylpurines, N2-aminoalkylpurines, 7- deaza-7-substituted purines, 5-substituted pyrimidines, and 2-substituted pyrimidines.
  • oligomeric compounds of the invention include oligoribonucleotides having nucleoside subunits connected by phosphorus linkages including phosphorothioate, 3 ' - (or -5 ') deoxy-3 ' - (or -5') thio- phosphorothioate, phosphoro-dithioate, phosphoroselenates, 3 ' - (or -5 ' ) deoxy phosphinates, borano phosphates, 3 ' - (or -5 ') deoxy-3 ' - (or 5'-) amino phosphoramidates, hydrogen phosphonates, borano phosphate esters, phosphoramidates, alkyl or aryl phosphonates and phospho- triester linkages.
  • a selected group of oligoribonucleotide linkages for use in linking the nucleosides of the second segment include phosphorothioate, phosphinates and phosphor-amidate
  • oligomeric compounds of the invention may also include oligoribonucleosides having nucleoside subunits connected by carbonate, carbamate, silyl, sulfur, sulfonate, sulfonamide, formacetal, thioformacetal , oxime, methyleneimino, methylenemethylimino, methylenehydrazo, methylenedimethylhydrazo and methyleneoxymethylimino linkages.
  • oligomeric compounds of the invention include having nucleoside subunits connected by alternating phosphorus and non-phosphorous linkages.
  • Such non-phosphorous linkages include carbonate, carbamate, silyl, sulfur, sulfonate, sulfonamide, formacetal, thioformacetal , oxime, methyleneimino, methylenemethylimino, methylenehydrazo, methylenedimethylhydrazo and methyleneoxymethylimino linkages while the phosphorous linkages include phosphodiester, phosphorothioate, 3 ' - (or -5 ' ) deoxy-3 ' - (or -5 ' ) thio-phosphorothioate, phosphorodithioate, phosphoroselenates, 3 ' - (or -5 ' ) deoxy phosphinates, borano phosphates, 3 ' - (or -5 ') deoxy-3 ' - (or 5'-) amino
  • oligomeric compounds of the invention include oligoribonucleotides, oligoribonucleosides or mixtures of oligoribonucleotides and oligoribonucleosides having a plurality 'of linked nucleoside subunits that are linked in a sequences that is complementary strand of target RNA and wherein the sequence of the compound is divided into a first subsequence or segment and a second subsequence or segment.
  • the first subsequence comprises linked nucleoside subunits bearing 2 ' -O-substituted- pentofuranosyl sugar moieties and the second subsequence comprises linked nucleoside subunits bearing 2'-hydroxyl- pentofuranosyl sugar moieties.
  • said second subsequence has from four to twelve or more nucleoside subunits, and more preferably, has five to about nine nucleoside subunits.
  • there exists a third subsequence the nucleoside subunits of which are selected from those which are selectable for the first subsequence. It is preferred that the second subsequence be positioned between the first and the third subsequences.
  • oligomeric compounds of the invention are also referred to as “chimeras, " “chimeric” or “gapped” oligoribonucleotides or oligoribonucleosides.
  • nucleoside subunits bearing substituents that are modified to improve at least one of: pharmacokinetic binding, absorption, distribution or clearance properties of the compound: affinity or specificity of said compound to said target RNA: or modification of the charge of said compound, compared to an unmodified compound; are located at one or both of the 3 ' or the 5 ' termini of the oligomeric compounds.
  • Each nucleoside subunit includes a base fragment and a sugar fragment.
  • the base fragment comprises a heterocyclic base, alternately hereinafter referred to as a nucleobase.
  • the bases or nucleobases are covalently bonded to the sugar fragment .
  • the sugar fragments may include a 2 ' -substituted sugar moiety, a 2 ' -hydroxyl sugar moiety or a sugar surrogate moiety.
  • Preferred nucleobases of the invention include purines and pyrimidines such as adenine, guanine, cytosine, uridine, and thymine, as well as other synthetic and natural nucleobases such as xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2 -propyl and other alkyl derivatives of adenine and guanine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil) , 4- thiouracil, 8-halo, amino, thiol, thioalkyl, hydroxyl and other 8-substituted adenines and guanines, 5- trifluoromethyl and other 5-substituted uracils and cyto-
  • purines and pyrimidines include those disclosed in United States Patents Nos. 3,687,808, 5,484,908, 5,459,255, 5,457,191 and 5,614,617 (corresponding to United States patent application serial number 07/971,978), and those disclosed in the Concise Encyclopedia Of Polymer Science And Engineering, pages 858-859, Kroschwitz, J.I., ed. John Wiley & Sons, 1990, and those disclosed by Englisch et al . , Angewandte Chemie, International Edi tion, 1991, 30, 613.
  • Preferred sugar fragments are pentoribofuranosyl sugar moieties, i.e., the "natural" sugar moiety of messenger ribonucleic acids.
  • Other sugar-like or sugar surrogate compounds suitable for use in the oligoribonucleotides or oligoribonucleosides of the invention include cyclobutyl nucleoside surrogates as described in U.S. Patent 5,359,044, pyrrolidine nucleoside surrogates as described in U.S. Patent 5,519,134, morpholino nucleoside surrogates as described in U.S. Patents 5,142,047 and 5,235,033, and in related patent disclosures, and PNA (peptide nucleic acid) nucleoside surrogates.
  • synthetic oligomeric compounds that are specifically hybridizable with a preselected RNA target and where the compounds include a first segment including at least one surrogate nucleoside subunit and a second segment comprising at least four ribofuranosyl nucleoside subunits located in a consecutive sequence and having 2 ' -hydroxyl moieties thereon. Further the nucleoside subunits of the oligomeric compound are connected by internucleoside linkages that are stable to degradation as compared to phosphodiester bonds .
  • synthetic oligomeric compounds that are specifically hybridizable with a preselected RNA target and that include a first segment having at least one ribofuranosyl nucleoside subunit that is not a DNA or RNA "major" building block nucleoside and a second segment that includes at least four consecutive ribofuranosyl nucleoside subunits having 2 ' -hydroxyl moieties thereon.
  • the nucleoside subunits of the compounds are connected by internucleoside linkages which are modified to stabilize the linkages from degradation as compared to phosphodiester linkages.
  • Nucleoside subunits that are not DNA or RNA major building block nucleosides as that term is used in connection with this invention are members of the group consisting of adenosine, 2 ' -deoxyadenosine, guanosine, 2'- deoxyguanosine, cytidine, 2 ' -deoxycytidine, uridine and 2 ' -deoxythymidine. As such, this group excludes “minor" nucleosides that may be found in tRNA or in other nucleic acids .
  • the invention also provides methods of for specifically cleaving preselected RNA. These methods include contacting the RNA with a compound that includes at least twelve ribofuranosyl nucleosides subunits joined in a sequence which is specifically hybridizable with the preselected RNA.
  • the nucleoside subunits are joined by internucleoside bonds that are stable to degradation as compared to phosphodiester bonds .
  • the compound has at least one segment that includes at least one modified nucleoside subunit, which modified nucleoside subunit is modified to improve at least one of pharmacokinetic binding, absorption, distribution or clearance properties of the compound; affinity or specificity of the compound to target RNA; or modification of the charge of the compound, compared to an unmodified compound.
  • the compound additionally includes a further segment having at least four ribonucleoside subunits .
  • the invention also provides methods for treating an organism having a disease characterized by the undesired production of a protein. These methods include contacting the organism with an oligomeric compound of the invention having a sequence of nucleoside subunits capable of specifically hybridizing with a complementary strand of ribonucleic acid with at least one of the nucleoside subunits being functionalized to modify one of more properties of the oligomeric compounds compared to native RNA.
  • the compound further includes a plurality of the nucleoside subunits having 2' -hydroxyl- pentofuranosyl sugar moieties .
  • compositions including a pharmaceutically effective amount of an oligomeric compound having a sequence of nucleoside subunits capable of specifically hybridizing with a complementary strand of RNA and wherein at least one of the nucleoside subunits is modified to improve at least one of pharmacokinetic binding, absorption, distribution or clearance properties of the compound; affinity or specificity of said compound to said target RNA; or modification of the charge of said compound, compared to an unmodified compound.
  • a plurality of the nucleoside subunits have 2' -hydroxyl- pentofuranosyl sugar moieties.
  • the compositions further include a pharmaceutically acceptable diluent or carrier.
  • the present invention also provides mammalian ribonucleases, isolatable from human T24 cells, other cell lines, and rat tissues, that degrade RNA in an oligoribonucleotide :RNA duplex.
  • a ribonuclease is referred to herein as a dsRNase, wherein "ds” indicates the RNase' s specificity for certain double-stranded RNA substrates.
  • Useful substrates for such dsRNases are also herein provided, as well as affinity matrices comprising such substrates.
  • Methods are also provided for in vi tro modification of a sequence-specific target RNA including contacting a test solution containing a dsRNase enzyme, i.e., a double stranded RNase enzyme, and said target RNA with an oligomeric compound.
  • the oligomeric compound has a sequence of nucleoside subunits capable of specifically hybridizing to a complementary strand of the nucleic acid, where at least one of the nucleoside subunits is functionalized to increase the binding affinity or binding specificity of the oligoribonucleotide to the complementary strand of nucleic acid, and where a plurality of the nucleoside subunits have 2 ' -hydroxyl- pentofuranosyl sugar moieties.
  • nucleoside subunits capable of specifically hybridizing to a complementary strand of target RNA.
  • At least one of the nucleoside subunits is modified to improve at least one of pharmacokinetic binding, absorption, distribution or clearance properties of the compound; affinity or specificity of said compound to said target RNA; or modification of the charge of said compound, compared to an unmodified compound.
  • a plurality of the nucleoside subunits have 2 ' -hydroxy- pentofuranosyl sugar moieties.
  • the invention further provides diagnostic methods for detecting the presence or absence of abnormal RNA molecules, or abnormal or inappropriate expression of normal RNA molecules in organisms or cells.
  • the invention further provides research reagents for modulating enzyme activity including dsRNase activity in in vi tro solutions.
  • Figure 1 schematically depicts certain illustrative chimeric oligomeric compounds of the invention wherein open squares represent 2 ' -methoxy modified ribonucleotides, filled circles represent 2'- hydroxyl ribonucleotides and phosphorothioate linkages are utilized through the compounds shown in the figure.
  • FIGS. 2A and C depict Ha-ras mRNA levels in cells treated with full 2 '-methoxy or chimeric RNA gapmer oligonucleotides.
  • Northern blot analyses for Ha-ras mRNA levels in T24 cells treated with the indicated doses of full 2 "-methoxy oligonucleotide (panel 2A) or 3 gap oligoribonucleotide (panel 2C) for 24 hrs . are shown.
  • the upper band is the signal for Ha-ras, this signal was normalized to that obtained for G3PDH (lower band) , relative Ha-ras levels were determined and are presented graphically (panels 2B-2D) .
  • oligonucleotide treatment reduced Ha-ras mRNA levels.
  • Figures 3A-3D show Northern blot analyses of T24 cell treated as in Figure 2 except with chimeric RNA gapmer oligonucleotides containing either a 5, 7 or 9 ribonucleotide gap or a full ribonucleotide molecule (left panels 3A, 3B, 3C and 3D, respectively) ; cells were also treated with a control oligoribonucleotide that contains four mismatched base pairs to the Ha-ras mRNA sequence (left panel 3E) .
  • Ha-ras signals were normalized to that of G3PDH and relative Ha-ras levels are shown graphically ( Figures 3A through 3E, respectively) .
  • Figure 5 shows the same 9 RNA gapmer oligonucleotide:RNA duplex as in Figure 4, incubated with or without E. coli RNase H (- and +, respectively) .
  • the lack of digestion products indicates that this duplex is not a substrate for RNase H.
  • Duplexes consisting of 32 P- labeled RNA annealed to either a full oligodeoxynucleotide (middle panel) or * 9 DNA gapmer oligonucleotide (left panel) are substrates for cleavage by RNase H and thus generate digestion products as expected (arrows) .
  • Figure 6 depicts SDS-polyacrylamide gel electrophoretic analysis of the concentrated rat liver active fractions after size exclusion chromatography. MW, molecular weight markers in kilodaltons (kD) .
  • Fraction 3 (lane 4) , having an apparent molecular weight in the range of about 35 to about 100 kD, with much of the material having an apparent molecular weight in the range 50 to about 80 kD, had the greatest amount of dsRNase activity.
  • Figure 7 shows analysis of products of digestion of dsRNAse substrates by native polyacrylamide gel electrophoresis. Antisense and sense oligonucleotides were preannealed and incubated with cellular extracts and purified dsRNases as decribed herein.
  • Lane 1 untreated "sense” strand RNA; lane 2, "sense” strand RNA treated with 0.02 units RNase VI; remaining lanes: dsRNAse substrates treated with 0.02 (lane 3) and 0.002 (lane 4) units of RNase VI, with unpurified nuclear extract for 0 minutes (lane 5) or 240 minutes (lane 6) , with unpurified nuclear extract for 240 minutes without Mg ++ (lane 7) , with unpurified cytosolic extract for 240 minutes (lane 8) , with ion exchange purified cytosolic extract for 240 minutes in the presence (lane 9) or absence (lane 10) of Mg ++ , and with ion exchange/gel filtration purified cytosolic extract for 240 minutes in the presence (lane 9) or absence (lane 10) of Mg ++ .
  • Figure 8 shows analysis of products of digestion of dsRNAse substrates by denaturing polyacrylamide gel electrophoresis.
  • Lane 1 "sense” strand RNA treated with 5 x 10 ⁇ 3 units of RNase A; lane 2, “sense” strand RNA treated with 0.02 units RNase VI; lanes 3-9: dsRNAse products treated with 0.02 (lane 3) and 0.002 (lane 4) units of RNase VI, with unpurified nuclear extract for 0 minutes (lane 5) or 240 minutes (lane 6) , with unpurified cytosolic extract for 240 minutes (lane 7) , with ion exchange purified cytosolic extract for 240 minutes (lane 8) , and with ion exchange/gel filtration purified cytosolic extract for 240 minutes (lane 9) .
  • Lane 10 base hydrolysis ladder.
  • the oligomeric compounds of the invention have certain RNA like features that allow them to form a double stranded structure with a targeted RNA region and this double stranded structure is subsequently degraded by eukaryotic dsRNases, i . e . double-stranded RNase enzymes, in a cell or test solution.
  • dsRNases i . e . double-stranded RNase enzymes
  • RNase H is highly sensitive to structural modifications made to the antisense oligonucleotides and thus most of the modifications designed to improve the therapeutic properties v such as increased affinity, increased nuclease resistance and greater cellular permeability have resulted in oligonucleotides that do not support cleavage by RNase E .
  • Another limitation to RNase H as a terminating mechanism of antisense action is the fact that the oligonucleotides must be DNA 'like', and in being DNA 'like', such oligonucleotides have inherently low affinity to their target RNA.
  • RNase H activity is primarily localized to the nucleus although it has been detected in the cytoplasm at lower levels. Most of a given mRNA is found in the cytoplasm of cells, therefore the ideal activity to be exploited as a terminating mechanism would be one with high levels in both the nucleus and the cytoplasm. RNase H activity also is highly variable from cell line to cell line or between tissues, thus a given disease state may not be a good candidate for RNA degradation only because the target tissue has insufficient RNase H activity. It is clear that alternative terminating mechanisms for degrading target RNA are highly desirable.
  • the activity that has now been recognized can now be exploited as an alternative terminating mechanism to RNase H for antisense therapeutics. It has been found that in using RNA-like oligonucleotides that have high affinity for their target and thus higher potency than DNA-like oligonucleotides, activity can be expressed in human cells. The presence of the activity in both the cytoplasm and the nucleus allows the compounds of the invention to be used to inhibit many RNA processing events from nuclear pre-mRNA splicing and transport to degradation of mature transcript in the cytoplasm. To illustrate this invention and to compare it to other known antisense mechanisms, e . g.
  • RNase H the dsRNAse activity induced by the compounds of the invention has been examined by targeting it to codon 12 of Ha -ras .
  • the ras oncogenes are members of a gene family that encode related proteins that are localized to the inner face of the plasma membrane and have been shown to be highly conserved at the amino acid level , to bind GTP with high affinity and specificity, and to possess GTPase activity.
  • ras gene products Although the cellular function of ras gene products is unknown, their biochemical properties, along with their significant sequence homology with a class of signal- transducing proteins, known as GTP binding proteins, or G proteins, suggest that ras gene products play a fundamental role in basic cellular regulatory functions related to the transduction of extracellular signals across plasma membranes .
  • H-ras Three ras genes, designated H-ras, K-ras, and N-ras, have been identified in the mammalian genome. Mammalian ras genes acquire transformation-inducing properties by single point mutations within their coding sequences. Mutations in naturally occurring ras oncogenes have been localized to codons 12, 13, and 61.
  • the most commonly detected activating ras mutation found in human tumors is in codon 12 of the H-ras gene in which a base change from GGC to GTC results in a glycine-to- valine substitution in the GTPase regulatory domain of the ras protein product .
  • This single amino acid change is thought to abolish normal control of ras protein function, thereby converting a normally regulated cell protein to one that is continuously active. It is believed that such deregulation of normal ras protein function is responsible for the transformation from normal to malignant growth.
  • the compounds of the invention are targeted to ras RNA, it is of course recognized that a host of other RNAs also are suitable as the target RNA.
  • the compounds of the invention can be used to modulate the expression of any suitable target RNA that is naturally present in cells or any target RNA in vi tro .
  • the ras target site utilized for illustrative purposes is one the most RNase H sensitive oligonucleotide sites that has been identified in the literature.
  • the selective inhibition of mutated genes such as the ras oncogene necessitates hybridization of a regulatory compound in the coding region of the mRNA. This requires either a high affinity interaction between such a compound and ras mRNA to prevent displacement of the compound by the polysome, or rapid degradation of the target mRNA by a given terminating mechanism.
  • the RNA like compounds of the invention have both inherently high affinity and are able to take advantage of the cellular dsRNase activity.
  • novel oligomeric compounds that bind to a target RNA strand and that are substrates for dsRNase enzymes are provided.
  • the oligomeric compounds of the invention include oligoribonucleotides, oligoribonucleosides and other oligomeric compounds having a linear sequence of linked ribonucleoside subunits incorporated therein.
  • Such other oligomeric compounds will include chimeric structures formed between
  • oligomeric compound is meant to be inclusive of the terms oligoribonucleotides and oligoribonucleosides, either used singly or in combination, as well as other oligomeric compounds including chimeric compounds formed between PNA segments (and other surrogate nucleoside components) and linked ribonucleoside segments.
  • oligomeric compound is used to represent oligoribonucleotides, in a further sense to represent oligoribonucleosides, in even a further sense to represent mixtures of oligoribonucleotides and oligoribonucleosides and in other instances to indicated further chimeric compounds such as the above identified PNA chimeric compounds.
  • the oligoribonucleotides and oligoribonucleosides of the invention are assembled from a plurality of nucleoside subunits.
  • at least one of the nucleoside subunits bear a substituent group that increases the binding affinity of the oligoribonucleotide or oligoribonucleoside for a complementary strand of nucleic acid.
  • at least some of the nucleoside subunits comprise 2 ' - hydroxyl-pentofuranosyl sugar moieties.
  • the oligonucleotide For cellular use, for an oligonucleotide to be particularly useful, the oligonucleotide must be reasonably stable to nucleases in order to survive in cells for a time period sufficient for it to interact with target nucleic acids of the cells. Therefore, in certain embodiments of the invention, specific nucleoside subunits or internucleoside linkages are functionalized or selected to increase the nuclease resistance of the oligoribonucleotide or oligoribonucleoside. However, for non-cellular uses, such as use of oligomeric compounds of the invention as research reagents and as diagnostic agents, such nuclease stability may not be necessary.
  • the relative ability of the first nucleic acid to bind to the complementary nucleic acid may be compared by determining the melting temperature of a particular hybridization complex.
  • the melting temperature (T m ) a characteristic physical property of double stranded nucleotides, denotes the temperature (in degrees centigrade) at which 50% helical (hybridized) versus coil
  • T m is measured by using the UV spectrum to determine the formation and breakdown (melting) of the hybridization complex.
  • Base stacking which occurs during hybridization is accompanied by a reduction in UV absorption (hypochromicity) .
  • substituent groups are 2' substituent groups, i.e. substituent groups located at the 2' position of the pentofuranosyl sugar moieties of the nucleoside subunits of the compounds of the present invention.
  • Presently preferred substituent groups include fluoro, alkoxy, aminoalkoxy, allyloxy, imidazolylalkoxy and polyethylene glycol.
  • Alkoxy and aminoalkoxy groups generally include lower alkyl groups, particularly C ⁇ -C 9 alkyl.
  • Polyethylene glycols are of the structure (0-CH 2 -CH 2 ) n -0- alkyl .
  • a further particularly useful 2 ' -substituent group for increasing the binding affinity is the 2 ' - fluoro group.
  • the 15-mer phosphodiester oligonucleotide was derivatized to the corresponding phosphorothioate analog.
  • the phosphorothioate analog had a binding affinity of only about 66% of that of the 15-mer phosphodiester oligonucleotide. Stated otherwise, binding affinity was lost in derivatizing the oligonucleotide to its phosphorothioate analog.
  • suitable nucleobases for incorporation in these nucleoside subunits include purines and pyrimidines such as adenine, guanine, cytosine, uridine, and thymine, as well as other synthetic and natural nucleobases such as xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2 -propyl and other alkyl derivatives of adenine and guanine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil) , 4- thiouracil, 8-halo, amino, thiol, thioalkyl, hydroxyl and other 8-substituted adenines
  • purines and pyrimidines include those disclosed in United States Patent No. 3,687,808, those disclosed in the Concise Encyclopedia Of Polymer Science And Engineering, pages 858-859, Kroschwitz, J.I., ed. John Wiley & Sons, 1990, and those disclosed by Englisch et al . , Angewandte Chemie, International Edi tion, 1991, 30, 613. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention.
  • 5-substituted pyrimidines include 5-substituted pyrimidines, 6- azapyrimidines and N-2, N-6 and 0-6 substituted purines, including 2 -aminopropyladenine, 5-propynyluracil and 5- propynylcytosine .
  • Other modified pyrimidine and purine bases are also expected to increase the binding affinity of oligomeric compounds to a complementary strand of nucleic acid.
  • Preferred oligoribonucleotides and oligoribonucleosides in accordance with this invention preferably comprise from about 5 to about 50 nucleoside subunits. In the context of this invention it is understood that this encompasses non-naturally occurring oligomers as hereinbefore described, having 5 to 50 nucleoside subunits. It is more preferred that the oligoribonucleotides and oligoribonucleosides of . the present invention comprise from about 15 to about 25 nucleoside subunits.
  • nucleoside subunit is a nucleobase and sugar or sugar surrogate combination suitably bound to adjacent subunits through phosphorus linkages in oligoribonucleotides and through non-phosphorus linkages in oligoribonucleosides.
  • nucleoside subunit is used interchangeably with the term “nucleoside unit” or
  • nucleoside The oligoribonucleotides of the invention have their nucleoside subunits connected by phosphorus linkages including phosphodiester, phosphorothioate, 3'-
  • oligoribonucleosides of the invention have their nucleoside subunits connected by carbonate, carbamate, silyl, sulfur, sulfonate, sulfonamide, formacetal, thioformacetyl, oxime, methyleneimino, methylenemethylimino, methylenehydrazo, methylenedimethylhydrazo and methyleneoxymethylimino linkages.
  • a segment or subsequence of greater than three, but preferably, four, five or more consecutively linked 2 ' -hydroxyl-pentofuranosyl-containing nucleoside subunits there will be a segment or subsequence of greater than three, but preferably, four, five or more consecutively linked 2 ' -hydroxyl-pentofuranosyl-containing nucleoside subunits. It is presently preferred to incorporate the 2 ' -hydroxyl-pentofuranosyl- containing nucleoside subsequence in the oligomeric compound such that further subsequences or segments of oligomeric compound are located on either side of the 2 ' - hydroxyl-pentofuranosyl-containing nucleoside subsequence.
  • nucleoside subsequence is also referred to as the "central” or “gap” region or segment and the other nucleoside subsequences or segments are referred to as "flanking" or "wing” regions or segments.
  • wings Other constructions are also possible, including locating the 2 ' -hydroxylpentofuranosyl containing nucleoside subsequence at either the 3 ' or the
  • oligoribonucleotides and oligoribonucleosides used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis, see for example "Oligonucleotide synthesis, a practical approach”, Ed. M.J. Gait, IRL Press, 1984; "Oligonucleotides and Analogues, A Practical Approach”, Ed. F.
  • oligonucleotides The actual synthesis of the oligonucleotides is well within the talents of those skilled in the art. It is also well known to use similar techniques to prepare other oligonucleotides such as the phosphorothioates and alkylated derivatives. It is also well known to use similar techniques and commercially available modified amidites and controlled-pore glass (CPG) products such as biotin, fluorescein, acridine or psoralen-modified amidites and/or CPG (available from Glen Research, Sterling VA) to synthesize fluorescently labeled, biotinylated or other conjugated oligonucleotides.
  • CPG controlled-pore glass
  • the present invention is drawn to a mammalian ribonuclease isolatable from human T24 cells, and other cell lines, that degrades RNA in an antisense oligoribonucleotide : NA duplex.
  • the ribonuclease is referred to herein as a dsRNase, wherein
  • ds indicates the RNase' s specificity for double- stranded RNA substrates.
  • Antisense oligodeoxynucleotides containing 2 "-methoxy modified sugar moieties bind to their cellular mRNA targets with high affinity but the resulting ["DNA-like” ] : [RNA] duplexes are not substrates for nucleolytic degradation in T24 cells.
  • oligonucleotides targeting codon 12 of Ha-Ras mRNA were modified by substituting 2 '-methoxy nucleotides with a stretch of ribonucleotides in the center of the oligonucleotide to form 2 '-methoxy/ribo/2 '-methoxy chimeric or "gapmer" oligonucleotides, with the phosphorothioate linkage maintained throughout the molecules.
  • RNA-like gapmer oligonucleotides bind to their cellular mRNA target with an affinity comparable to that of the full 2 '-methoxy oligodeoxynucleotide, but, unlike the ["DNA-like”] : [RNA] duplexes, the resultant
  • [RNA] duplexes are substrates for nucleolytic degradation in T24 cells. Degradation of the
  • [antisense "RNA-like” gapmer 1 oligonucleotide] [Ha-Ras mRNA] duplex is dependent on the number of ribonucleotides incorporated into the antisense molecule.
  • RNA duplex is not a substrate for RNase H cleavage, but is a substrate for cleavage by an the dsRNase of the invention in T24 cellular lysates. Furthermore, the cleavage sites seen with T24 cellular lysates are localized to the RNA:RNA portion of the duplex and are not seen in the 2'- methoxy: RNA portion of the duplex. Cleavage of the duplex by the dsRNase of the invention produces 5'- phosphate and 3 '-hydroxyl termini.
  • Compounds of the invention can be utilized as diagnostics, therapeutics and as research reagents and kits. They can be utilized in pharmaceutical compositions by adding an effective amount of a compound of the invention to a suitable pharmaceutically acceptable diluent or carrier. They further can be used for treating organisms having a disease characterized by the undesired production of a protein. The organism can be contacted with a compound of the invention having a sequence that is capable of specifically hybridizing with a strand of target nucleic acid that codes for the unde- sirable protein.
  • a patient in need of such therapy is administered a compound in accordance with the invention, commonly in a pharmaceutically acceptable carrier, in doses ranging from 0.01 ⁇ g to 100 g per kg of body weight depending on the age of the patient and the severity of the disease state being treated.
  • the treatment regimen may last for a period of time which will vary depending upon the nature of the particular disease, its severity and the overall condition of the -patient, and may extend from once daily to once every 20 years.
  • the patient is monitored for changes in his/her condition and for alleviation of the symptoms of the disease state.
  • the dosage of the compound may either be increased in the event the patient does not respond significantly to current dosage levels, or the dose may be decreased if an alleviation of the symptoms of the disease state is observed, or if the disease state has been ablated.
  • a patient being treated for a viral disease may be administered a compound of the invention in conjunction with a known antiviral agent, or a patient with atherosclerosis may be treated with a compound of the invention following angioplasty to prevent reocclusion of the treated arteries.
  • the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the compound of the invention is administered in maintenance doses, ranging from 0.01 ⁇ g to 100 g per kg of body weight, once or more daily, to once every 20 years .
  • compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic, vaginal, rectal, intranasal, transdermal), oral or parenteral. Parenteral administration includes intravenous drip, subcutaneous, intraperitoneal or intramuscular injection, or intrathecal or intraventricular administration.
  • Formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders.
  • compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets or tablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable.
  • Compositions for intrathecal or intraventricular administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives.
  • Formulations for parenteral administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives.
  • Dosing is dependent on severity and responsiveness of the disease condition to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of disease state is achieved.
  • Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates.
  • Optimum dosages may vary depending on the relative potency of individual compounds, and can generally be estimated based on EC 50 s found to be effective in in vi tro and in vivo animal models. In general, dosage is from 0.01 ⁇ g to 100 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years.
  • Such treatment can be practiced in a variety of organisms ranging from unicellular prokaryotic and eukaryotic organisms to multicellular eukaryotic organisms.
  • Any organism that utilizes DNA-RNA transcription or RNA- protein translation as a fundamental part of its hereditary, metabolic or cellular machinery is susceptible to such diagnostic, therapeutic and/or prophylactic treatment. Seemingly diverse organisms such as bacteria, yeast, protozoa, algae, plant and higher animal forms, including warm-blooded animals, can be treated in this manner.
  • each of the cells of multicellular eukaryotes also includes both DNA-RNA transcription and RNA-protein translation as an integral part of their cellular activity, such therapeutics and/or diagnostics can also be practiced on such cellular populations.
  • organelles e . g. mitochondria and chloroplasts
  • many of the organelles, e . g. mitochondria and chloroplasts, of eukaryotic cells also include transcription and translation mechanisms.
  • single cells, cellular populations or organelles also can be included within the definition of organisms that are capable of being treated with the therapeutic or diagnostic compounds of the invention.
  • therapeutics is meant to include eradication of a disease state, killing of an organism, e . g. bacterial, protozoan or other infection, or control of aberrant or undesirable cellular growth or expression.
  • target RNA shall mean any RNA that can hybridize with a complementary nucleic acid like compound.
  • hybridization shall mean hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleobases.
  • oligomeric compound of the invention need not be 100% complementary to its target RNA sequence to be specifically hybridizable.
  • An oligomeric compound is specifically hybridizable when binding of the oligomeric compound to the target RNA molecule interferes with the normal function of the target RNA to cause a loss of utility, and there is a sufficient degree of complementarity to avoid nonspecific binding of the oligomeric compound to non-target sequences under conditions in which specific binding is desired, i.e. under physiological conditions in the case of in vivo assays or therapeutic treatment, or in the case of in vi tro assays, under conditions in which the assays are performed.
  • Example 1 identifies certain commercial nucleoside amidites and other additional nucleoside amidites that are useful for the preparation of certain illustrative oligoribonucleotide or oligoribonucleoside compounds of the invention.
  • Examples 2 through 5 illustrate the preparation of further nucleoside amidites use in preparing other illustrative oligoribonucleotide or oligoribonucleoside compounds of the invention.
  • Example 6 illustrates the preparation of oligoribonucleotide compounds of the invention.
  • Example 7 illustrates the preparation of oligoribonucleoside compounds of the invention.
  • Examples 8 through 16 illustrate the preparation of chimeric oligomeric compounds of the invention including certain "gapmers,” i.e., compounds having "gap” and “wing” constructions.
  • Examples 17 through 18 illustrate certain useful aspects of the compounds of the invention.
  • Examples 19 through 28 illustrate the identification, characterization and purification of the double-stranded ribonucleases (dsRNases) of the invention.
  • Example 29 illustrates affinity columns incorporating the dsRNase substrates of the invention.
  • dsRNases double-stranded ribonucleases
  • oligoribonucleosides include a first type wherein the "gap" segment of linked nucleosides is positioned between 5 ' and 3 ' "wing” segments of linked nucleosides and a second "open end” type wherein the "gap” segment is located at either the 3' or the 5' terminus of the oligomeric compound.
  • 2 ' -O-methyl nucleosides are utilized in the "wing” segments and 2 ' -OH nucleosides are utilized in the "gap" segments of the respective oligoribonucleotides or oligoribonucleosides.
  • nucleosides PO for phosphodiester; PS for phosphorothioate, P2S for phosphorodithioate, PSe for phosphoroselenates, PMe for methyl phosphonate, POMe for methyl phosphotriester, PN for phosphoramidate, 3'NPN for 3 ⁇ -deoxy-3 ' -amino phosphoramidate, PI for phosphinate, MePS for alkylphosphonothioate, BP for borano phosphate are used.
  • MMI methylenemethylimino
  • MDH methylenedimethylhydrazo
  • FA formacetal
  • TFA thioformacetal
  • ETO ethylene oxide
  • amide-3 methylenecarbonylamino. 2 • -OH is utilized as an abbreviation for unmodified ribo sugars, i.e. pentoribofuranosyl sugars.
  • Mod- Purine for a purine nucleobase substitution as, for example, per the disclosure of U.S.
  • 2 ' -O-Methyl nucleoside amidites and 2 ' -OH (blocked as 2 ' - t-butyldimethylsilyl derivative) nucleoside amidites are available from Glen Research, Sterling, VA.
  • Other 2 ' -O-alkyl subsituted nucleoside amidites are prepared as is described in U.S. Patents 5,506,351, 5,466,786 or 5,514,786, herein incorporated by reference.
  • Cyclobutyl sugar surrogate compounds are prepared as is described in U.S. Patent 5,359,044, herein incorporated by reference.
  • Pyrrolidine sugar surrogate are prepared as is described in U.S. Patent 5,519,134, herein incorporated by reference.
  • Morpholino sugar surrogates are prepared as is described in U.S. Patents 5,142,047 and 5,235,033, herein incorporated by reference, and other related patent disclosures.
  • N-2 substituted purine nucleoside amidites are prepared as is described in U.S. Patent 5,459,255, herein incorporated by reference.
  • 3-Deaza purine nucleoside amidites are prepared as is described in U.S. Patent 5,457,191, herein incorporated by reference.
  • 5, 6-Substituted pyrimidine nucleoside amidites are prepared as is described in U.S. Patent 5,614,617 herein incorporated by reference.
  • 5- Propynyl pyrimidine nucleoside amidites are prepared as is described in U.S. Patent 5,484,908, herein incorporated by reference.
  • the solution was poured into fresh ether (2.5 L) to yield a stiff gum.
  • the ether was decanted and the gum was dried in a vacuum oven (60°C at 1 mm Hg for 24 h) to give a solid which was crushed to a light tan powder (57 g, 85% crude yield) .
  • the NMR spectrum was consistent with the structure, contaminated with phenol as its sodium salt (ca. 5%) .
  • the material was used as is for further reactions (or it can be purified further by column chromatography using a gradient of methanol in ethyl acetate (10-25%) to give a white solid, mp 222-4°C) .
  • 2,2 ' -Anhydro-5-methyluridine (195 g, 0.81 M) , tris (2-methoxyethyl)borate (231 g, 0.98 M) and 2 - methoxyethanol (1.2 L) were added to a 2 L stainless steel pressure vessel and placed in a pre-heated oil bath at 160°C. After heating for 48 hours at 155-160°C, the vessel was opened and the solution evaporated to dryness and triturated with MeOH (200 mL) . The residue was suspended in hot acetone (1 L) . The insoluble salts were filtered, washed with acetone (150 mL) and the filtrate evaporated.
  • the reaction was monitored by tic by first quenching the tic sample with the addition of MeOH. Upon completion of the reaction, as judged by tic, MeOH (50 mL) was added and the mixture evaporated at 35°C. The residue was dissolved in CHC1 3 (800 mL) and extracted with 2x200 mL of saturated sodium bicarbonate and 2x200 mL of saturated NaCl. The water layers were back extracted with 200 mL of CHC1 3 . The combined organics were dried with sodium sulfate and evaporate to give 122 g of residue (approx. 90% product) . The residue was purified on a 3.5 kg silica gel column and eluted using EtOAc/Hexane (4 : 1) . Pure product fractions were evaporated to yield 96 g (84%) . An additional 1.5 g was recovered from later fractions .
  • a first solution was prepared by dissolving 3 ' -O-acetyl-2 ' -O-methoxyethyl-5 ' -O-dimethoxytrityl-5- methyluridine (96 g, 0.144 M) in CH 3 CN (700 L) and set aside. Triethylamine (189 mL, 1.44 M) was added to a solution of triazole (90 g, 1.3 M) in CH 3 CN (1 L) , cooled to -5°C and stirred for 0.5 h using an overhead stirrer. POCl 3 was added dropwise, over a 30 minute period, to the stirred solution maintained at 0-10°C, and the resulting mixture stirred for an additional 2 hours.
  • the first solution was added dropwise, over a 45 minute period, to the later solution.
  • the resulting reaction mixture was stored overnight in a cold room. Salts were filtered from the reaction mixture and the solution was evaporated. The residue was dissolved in EtOAc (1 L) and the insoluble solids were removed by filtration. The filtrate was washed with 1x300 mL of NaHC0 3 and 2x300 mL of saturated NaCl, dried over sodium sulfate and evaporated. The residue was triturated with EtOAc to give the title compound.
  • N-Benzoyl-2 ' -O-methoxyethyl-5 ' -O- dimethoxytrityl-5 -methylcytidine (74 g, 0.10 M) was dissolved in CH 2 Cl 2 (1 L) .
  • Tetrazole diisopropylamine (7.1 g) and 2-cyanoethoxy-tetra (isopropyl) phosphite (40.5 mL, 0.123 M) were added with stirring, under a nitrogen atmosphere. The resulting mixture was stirred for 20 hours at room temperature (tic showed the reaction to be 95% complete) .
  • the reaction mixture was extracted with saturated NaHC0 3 (1x300 mL) and saturated NaCl (3x300 mL) .
  • the aqueous washes were back-extracted with CH 2 C1 2
  • 6-Diamino-9- (2-O-octadecyl- ⁇ -D- ribofuranosyl) purine (10 g) in 0.1 M sodium phosphate buffer (50 mL, pH 7.4), 0.1 M tris buffer (1000 mL, pH 7.4) and DMSO (1000 mL) was treated with adenosine deaminase (1.5 g) at RT.
  • adenosine deaminase 1.5 g
  • day 3 day 5 and day 7 an additional aliquot (500 mg, 880 mg and 200 mg, respectively) of adenosine deaminase was added. The reaction was stirred for a total of 9 day and purification by silica gel chromatography yielded the product (2 g) .
  • reaction mixture was allowed to warm to 20°C and stirred for 2 hours. After cooling the reaction mixture to 0°C, cold water (8 mL) was added and the mixture was stirred for 15 minutes. Concentrated ammonium hydroxide (8 mL) was slowly added to the reaction mixture to give a final concentration of 2 M of ammonia. After stirring the cold reaction mixture for 30 minutes, the solvent was evaporated in vacuo (60 torr) at 20°C followed by evaporation in vacuo (1 torr) at 40°C to give an oil. This oil was triturated with diethyl ether (50 .mL) to give a solid which was filtered and washed with diethyl ether three times.
  • N ⁇ -Benzoyl-9-/3-D-arabinofuranosyladenine (2.62 g, 7.06 mmol) was dissolved in anhydrous dimethylformamide (150 mL) under argon and p-toluenesulfonic acid monohydrate (1.32 g, 6.92 mmol) was added. This solution was cooled to 0°C and dihydropyran (1.26 mL, 13.8 mmol) was added via a syringe. The reaction mixture was I allowed to warm to 20°C. Over a period of 5 hours a total of 10 equivalents of dihydropyran were added in 2 equivalent amounts in the fashion described. The reaction mixture was cooled to 0°C and saturated aqueous sodium bicarbonate was added slowly to a pH of 8, then water was added to a volume of
  • N 6 -Benzoyl-9- [3 ' , 5 ' -di-O-tetrahydropyran-2-yl) /3-D- arabinofuranosyl] adenine (2.65 g, 4.91 mmol) was dissolved in anhydrous pyridine (20 mL) and the solvent was evaporated in vacuo (1 mm Hg) at 40°C. The resulting oil was dissolved in anhydrous methylene chloride (130 mL) under argon anhydrous pyridine (3.34 mL, 41.3 mmol) and N,N-dimethylaminopyridine (1.95 g, 16.0 mmol) were added.
  • N-4- (1,2,4-triazol-l-yl) -3 ' , 5 ' -O-diacetyl-2 ' - deoxy-2 ' -fluorouridine was obtained in a 70% yield (2.37 g) by reaction of 3',5'- O-diacetyl-2 ' -deoxy-2 ' -fluorouridine (2.75 g, 9.61 mmol) with 1, 2 , 4-triazole (5.97 g, 86.5 mmol), phosphorus oxychloride (1.73 mL, 18.4 mmol), and triethylamine (11.5 mL, 82.7 mmol) in anhydrous acetonitrile at room temperature.
  • 2 ' -deoxy-2 ' -fluorocytidine was afforded by treatment of protected triazol-1-yl derivative with concentrated ammonium hydroxide (4.26 mL, 81.2 mmol) in dioxane at room temperature for 6 hours. After evaporation of the solvent the oil was stirred in half-saturated (at ice temperature) ammonia in methanol for 16 hours. The solvent was evaporated and 2 ' -deoxy-2 ' -fluoro-cytidine crystallized from ethyl- acetate-methanol (v/v, 75:25) to give colorless crystals ( 1 . 24 g , 75 % ) .
  • N-4-benzoyl-2 ' -deoxy-2 ' -fluorocytidine was prepared by selective benzoylation with benzoic anhydride in anhydrous dimethylformamide, V. Bhat, et al . Nucleosides Nucleotides, Vol. 8, pp. 179-183 (1989).
  • N 2 -Isobutyryl-9- (2 ' -isobutyryl-3 ' , 5 ' - [1, 1, 3 , 3- tetraisopropyldisilox-1, 3-diyl] - ⁇ -D- arabinofuranosyl) guanine (9.83 g, 0.01476 mol) was dissolved in anhydrous THF (87.4 mL) at room temperature under argon. 1 M (nBu) 4 N + F " in THF (29.52 mL, 2 eq.) was added and the reaction mixture stirred for 30 minutes.
  • N 2 -Isobutyryl-9- (2 ' -isobutyryl- ⁇ -D- arabinofuranosyl) guanine (4.9 g) was dissolved in anhydrous 1,4-dioxane (98 mL) at room temperature under argon.
  • p-Toluenesulphonic acid monohydrate (0.97 g) was added followed by 3 , 4-dihydro-2H-pyran (DHP, 9.34 mL, 8.8 eq.) .
  • DHP 4-dihydro-2H-pyran
  • the reaction mixture was extracted three times with 125 mL portions of CH 2 C1 2 and the organic phase dried over MgS0 4 .
  • the organic phase was evaporated and the residue dissolved in minimum volume of CH 2 C1 2 , but in an amount sufficient to yield a clear liquid not a syrup, and then dripped into hexane (100 times the volume of CH 2 C1 2 ) .
  • the precipitate was filtered to yield 5.59 (81.5%) of product.
  • N 2 -Isobutyryl-9- (2 ' -isobutyryl -3 ' ,5' -di-O- [tetrahydropyran-2-yl] - ⁇ -D-arabinofuranosyl) guanine (5.58 g) was dissolved in pyridine-MeOH-H 2 0 (65:30:15, 52 mL) at room temperature. The solution was cooled to 0°C and 52 mL of 2 N NaOH in EtOH-MeOH (95:5) was added slowly, followed by stirring for 2 hours at 0°C. Glacial acetic acid was added to pH 6, and saturated NaHC0 3 was added to pH 7.
  • N 2 -Isobutyryl-9- (3 ' , 5 ' -di-O- [tetrahydropyran-2- yl] - ⁇ -D-arabinofuranosyl) guanine (3.84 g) was dissolved in anhydrous CH 2 C1 2 (79 mL) , anhydrous pyridine (5 mL) and DMAP (2.93 g) at room temperature under argon. The solution was cooled to 0°C and trifluoromethanesulfonic anhydride (1.99 L) was slowly added with stirring. The reaction mixture was stirred at room temperature for 1 hour then poured into 100 mL of saturated NaHC0 3 . The aqueous phase was extracted three times with cold CH 2 C1 2 .
  • reaction mixture was evaporated under reduced pressure and the residue dissolved in CH 2 C1 2 (160 mL) and extracted five times with deionized water. The organic phase was dried over MgS0 4 and evaporated. The residue was purified by silica gel column chromatography using EtOAc-MeOH (95:5) to yield 5.25 g of product .
  • N 2 -Isobutyryl-9- (2 • -deoxy-2 ' -fluoro- ⁇ -D- ribofuranosyl) guanine .
  • N 2 -isobutyryl-9- (2 ' -deoxy-2 ' -fluoro-3 ' , 5 ' -di-O-
  • N 2 -isobutyryl-9- (2 ' -deoxy-2 ' -fluoro- ⁇ -D-ribo- furanosyl) guanine (1.09 g) was dissolved in pyridine (20 mL) and triethylamine (0.56 mL) at room temperature under argon. 4 , 4 ' -Dimethoxytrityl chloride (1.20 g, 1.15 molar eq.) was added and the reaction mixture stirred at room temperature for 5 hours . The mixture was transferred to a separatory funnel and extracted with diethyl ether (100 L) . The organic phase was washed with saturated NaHC0 3
  • nucleoside amidites i. 1- (2 -Fluoro-/3-D-erythro-pentof ranosyl) -5- methyluridine
  • the formed 1- (2-phenyl-/3-D-erythro-pentofuranosyl) -5- methyluridine was converted into its DMT/phosphoramidite using the same reaction conditions as for the 2 ' -Fluoro material .
  • the mixture was stirred for 16 hours.
  • the mixture was washed with saturated sodium bicarbonate (1 L) and the bicarbonate solution was back extracted with dichloromethane (500 mL) .
  • the combined organic layers were washed with brine (1 L) and the brine was back extracted with dichloromethane (100 L) .
  • the combined organic layers were dried over sodium sulfate, filtered, and concentrated to a vol of about 200 mL.
  • the resulting material was purified by silica gel column chromatography using hexane/ethyl acetate/triethyl amine 60/40/1.
  • EXAMPLE 5-b i. 4-Triazine-l- (3 ' ,5 ' -di-0-acetyl-2-fluoro-/3-D ⁇ erythro- pentof ranosyl) -5-methyluridine 1,2,4-Triazole (106g, 1.53 mol) was dissolved in acetonitrile (150 mL) followed by triethylamine (257 mL, 1.84 mol) . The mixture was cooled to between 0 and 10 oC using an ice bath. P0C1 3 (34.5 mL, .375 mol) was added slowly via addition funnel and the mixture was stirred for an additional 45 minutes.
  • reaction mixture was concentrated in vacuo and the resulting residue purified by silica gel column chromatography using 60:40 hexane/ethyl acetate with 1% triethylamine used throughout. The pooling and concentration of appropriate fractions gave 1.32g (26%) of the title compound.
  • the resultant residue was purified by silica gel column chromatography using ethyl acetate/hexane 40:60 and 1% triethylamine. The appropriate fractions were pooled, concentrated, and dried under high vacuum to give 43g (67%) .
  • Triazole (10.5g, 152 mmol) was dissolved in acetonitrile (120 ml) and triethylamine (23 mL) with stirring under anhydrous conditions. The resulting solution was cooled in a dry ice acetone bath and phosphorous oxychloride (3.9 mL, 41 mmol) was added slowly over a period of 5 minutes. The mixture was stirred for an additional 10 minutes becoming a thin slurry indicative of product formation.
  • the reaction mixture was concentrated in vacuo and redissolved in ethyl acetate (300 mL) and extracted with saturated sodium bicarbonate solution (2 x 400 mL) and brine (400 mL) .
  • the aqueous layers were back extracted with ethyl acetate (200 mL) .
  • the ethyl acetate layers were combined, dried over sodium sulfate, and concentrated in vacuo .
  • the crude yield was 11.3g (95%) .
  • the NMR was consistent with the expected structure of the title compound. This material was used without further purification in subsequent reactions.
  • the reaction mixture was washed with saturated sodium bicarbonate solution (2 x 40 mL) and brine (1 x 40 mL) .
  • the aqueous layers were back extracted with dichloromethane.
  • the dichloromethane layers were combined, dried over sodium sulfate, filtered, and concentrated in vacuo .
  • the resultant residue was purified by silica gel column chromatography using ethyl acetate/hexane 40:60 and 1% triethylamine. ' The appropriate fractions were pooled, concentrated, and dried under high vacuum to give 7.3g (98%) .
  • Example 2-a Crude 2, 2 ' -anhydro-5 -methyluridine (10.0 g, 0.0416 mol) (Example 2-a) was dissolved in methanol (80 mL) in a stainless steel bomb (100 mL capacity) . Trimethyl borate (5.6 mL, 0.049 mol) was added (Note 1) . The bomb was sealed and placed in an oil bath at
  • the trialkyl borates can be conveniently generated by adding solutions (eg 1 M in THF) of borane to the desired alcohol and allowing the resulting hydrogen gas to evolve.)
  • the nucleoside can be purified at this point by column chromatography using a gradient of methanol in ethyl acetate (0-10%) and crystallizing the product from absolute ethanol to give white needles, mp 192-193° (mp 197-198°) .
  • Literature reference for the melting point of this compound is contained in E. Ootsuka, H. Inoue, Japanese Patent 89- 85456, 4 April 1989. Procedure 2 :
  • the foam was dissolved in methylene chloride (60 mL) and put onto a silica gel column (300 g) and eluted with ethyl acetate-hexanes-triethylamine, 60:40:1.
  • the product containing fractions were combined, concentrated and coevaporated with dry acetonitrile (2x 50 mL) .
  • the resulting residue was dried at 1 mm Hg for 24 h to a crisp white foam, 17.0 g (60.4% in three steps from 5- methyluridine) .
  • reaction mixture is cooled to room temperature and diluted with methylene chloride and chromatographed using a methylene chloride/methanol gradient . The appropriate fractions are collected and concentrated to give 2 ' -O- methyl -5-methyl -2 -thiouridine .
  • the aqueous layer was extracted with two additional portions of chloroform and the organic layers combined and dried with magnesium sulfate. After removal of the drying agent via filtration the filtrate was concentrated to an orange oil and purified by silica gel column chromatography using methanol/chloroform gradient with 0.5% pyridine added to neutralize the silica gel.
  • the protected nucleoside was purified by silica gel column chromatography using a hexane/ethyl acetate gradient.
  • the desired product was collected as a mixture of N-3 toluoyl and S-2 Toluoyl compounds. This mixture was used as is for the phosphyt-ilation procedure .
  • the solution was partitioned ⁇ between 75 mL of saturated sodium bicarbonate and 50 mL of chloroform.
  • the aqueous layer was extracted with two additional portions of chloroform and the organic layers combined and dried with magnesium sulfate. After removal of the drying agent via filtration the filtrate was concentrated to an orange oil and purified by silica gel column chromatography using methanol/chloroform gradient with
  • Example 5- k-iv The thioanhydronucleoside found in Example 5- k-iv was dissolved in anhydrous dioxane. To this solution was added 6 equivalents of HF/Pyridine complex and the reaction stirred until complete by TLC. The reaction mixture is then poured over an equal volume of ice and calcium carbonate is added until neutral. The solids are filtered off and the filtrate is concentrated. The residue is purified by silica gel column chromatography to give the title compound.
  • Unsubstituted and substituted phosphodiester oligoribonucleotides also identified herein as PO linked oligoribonucleotides, were synthesized on an automated DNA synthesizer (Applied Biosystems model 380B) using standard phosphoramidite chemistry with oxidation by iodine.
  • Phosphorothioate oligonucleotides also identified herein as PS linked oligoribonucleotides, are synthesized as per the phosphodiester oligoribonucleotides except the standard oxidation bottle was replaced by 0.2 M solution of 3H-1,2- benzodithiole-3-one 1,1-dioxide in acetonitrile for the step wise thiation of the phosphite linkages.
  • the thiation wait step was increased to 68 sec and was followed by the capping step.
  • Phosphinate oligoribonucleotides also identified herein as PI linked oligoribonucleotides, are prepared as is described in U.S. Patent 5,508,270, herein incorporated by reference.
  • Alkyl phosphonate oligoribonucleotides also identified herein as PMe linked oligoribonucleotides, are prepared as is described in U.S. Patent 4,469,863, herein incorporated by reference.
  • Phosphoramidite oligoribonucleotides also identified herein as PN linked oligoribonucleotides, are prepared as is described in U.S. Patent, 5,256,775 or U.S. Patent 5,366,878, herein incorporated by reference.
  • Alkylphosphonothioate oligoribonucleotides are prepared as is described in published PCT applications PCT/US94/00902 and PCT/US93/06976 (published as WO 94/17093 and WO 94/02499, respectively) , herein incorporate by reference .
  • 3 ' -Deoxy-3 ' -amino phosphoramidate oligoribonucleotide also identified herein as 3"NPN linked oligoribonucleotides, are prepared as is described in
  • Phosphotriester oligoribonucleotides also identified herein as POMe linked oligoribonucleotides, are prepared as is described in U.S. Patent 5,023,243, herein incorporated by reference.
  • Borano phosphate oligoribonucleotide also identified herein as BP linked oligoribonucleotides, are prepared as is described in U.S. Patents 5,130,302 and 5,177,198, both herein incorporated by reference.
  • EXAMPLE 7 -a Oligoribonucleoside synthesis Methylenemethylimino linked oligoribonucleosides, also identified herein as MMI linked oligoribonucleosides, methylenedimethylhydrazo linked oligoribonucleosides, also identified herein as MDH linked oligoribonucleosides, and methylenecarbonylamino linked oligonucleosides, also identified herein as amide-3 linked oligoribonucleosides, and methyleneaminocarbonyl linked oligonucleosides, also identified herein as amide-4 linked oligoribonucleosides as well as mixed backbone compounds having, as for instance, alternating MMI and PO or PS linkages are prepared as is described in U.S.
  • Formacetal and thioformacetal linked oligoribonucleosides are prepared as is described in U.S. Patents 5,264,562 and 5,264,564, herein incorporated by reference.
  • Ethylene oxide linked oligoribonucleosides also herein identified as ETO linked oligoribonucleosides, are prepared as is described in U.S. Patent 5,223,618, herein incorporated by reference .
  • PNAs Peptide Nucleic Acids
  • PNA Peptide Nucleic Acids
  • Oligoribonucleotides were synthesized using the automated synthesizer and 5 ' -dimethoxytrityl - 2 ' -tert-butyldimethylsilyl 3 ' -0-phosphoramidite for the RNA portion and 5 ' -dimethoxytrityl-2 ' -0-methyl-3 ' -0- phosphroamidite for 5' and 3' wings.
  • the protecting groups on the exocyclic amines were, phenoxyacetyl for rA and rG, benzoyl for rC and 2' -0-methyl A and 2 ' -0- methyl C, and isobutyryl for 2 ' -0 -methyl G.
  • the standard synthesis cycle was modified by increasing the wait step after the delivery of tetrazole and base to 600 s repeated four times for RNA and twice for 2'-0- methyl .
  • the fully protected oligoribonucleotide was cleaved from the support and the phosphate group was deprotected in 3:1 Ammonia/Ethanol at room temperature overnight then lyophilized to dryness.
  • Treatment in methanolic ammonia for 24 hrs at room temperature was then done to deprotect all bases and sample was again lyophilized to dryness.
  • the pellet was resuspended in IM TBAF in THF for 24 hrs at room temperature to deprotect the 2' positions.
  • the reaction is then quenched with IM TEAA and the sample is then reduced to 1/2 volume by rotovac before being desalted on a G25 size exclusion column.
  • the oligo recovered was then analyzed spectrophotometrically for yield and for purity by capillary electrophoresis and by mass spectrometer.
  • Example 8 using oligoribonucleotides of Example 6, a chimeric oligoribonucleotide having a 3 ' -deoxy-3 ' -amino phosphoramidate backbone is prepared.
  • Example 8 using oligoribonucleotides of Example 6, a chimeric oligoribonucleotide having a phosphinate backbone is prepared.
  • Example 8 using oligoribo- nucleotides of Example 6, a chimeric oligoribonucleotide having a phosphonothioate backbone is prepared.
  • Example 8 using oligoribonucleotides of Example 6, a chimeric oligoribonucleotide having a phosphorodithioate backbone is prepared.
  • Example 8 using oligoribonucleotides of Example 6, a chimeric oligoribonucleotide having a phosphoselenate backbone is prepared.
  • Example 8 using oligoribonucleotides of Example 6, a chimeric oligoribonucleo- tide having a methyl phosphotriester backbone is prepared.
  • Chimeric oligoribonucleosides i. Chimeric methylenemethyimino oligoribonucleoside, e . g. [2 • -O-Me] /MMI- [2 • -OH] /MMI- [-2 ' -O-Me] /MMI oligoribonucleoside
  • Example 8 In the manner of Example 8 using the chemistry of Example 7, a chimeric oligoribonucleoside having methylenemethylimino linkages throughout the oligoribonucleoside is prepared.
  • Example 8 In the manner of Example 8 using the chemistry of Example 7, a chimeric oligoribonucleoside having methylenedimethylhydrazo linkages throughout the oligoribonucleoside is prepared.
  • Example 8 In the manner of Example 8 using the chemistry of Example 7, a chimeric oligoribonucleoside having formacetal linkages throughout the oligoribonucleoside is prepared.
  • Example 8 In the manner of Example 8 using the chemistry of Example 7, a chimeric oligoribonucleoside having thioformacetal linkages throughout the oligoribonucleoside is prepared.
  • Example 8 In the manner of Example 8 using the chemistry of Example 7, a chimeric oligoribonucleoside having ethylene oxide linkages throughout the oligoribonucleoside is prepared.
  • Example 8 In the manner of Example 8 using the chemistry of Example 7, a chimeric oligoribonucleoside having amide-3 linkages throughout the oligoribonucleoside is prepared.
  • Example 8 In the manner of Example 8 using the chemistry of Examples 6 and 7, a chimeric compound having both oligoribonucleotide and oligoribonucleoside segments is prepared.
  • the chimeric compounds has methylenemethylimino linkages in one "wing” and phosphorothioate linkages in a central "gap" and in the other "wing. "
  • Example 8 Chimeric Methyl phosphonate/methylene- methylimino/phosphorothioate oligoribonucleotide/oligoribonucleoside, e . g. [2 ' -0- Me] /PMe- [2 • -OH] /PS- [-2 ⁇ -O-Me] /MMI oligoribonucleo- tide/oligoribonucleoside
  • a chimeric compound having both oligoribonucleotide and oligoribonucleoside portions is prepared.
  • the chimeric compound has methylenemethylimino linkages in one "wing", a phosphorothioate linkages in a central "gap" and methyl phosphonate linkages in the other "wing.”
  • Example 8 In the manner of Example 8 using the chemistry of Examples 6 and 7, a chimeric compound having both .oligoribonucleotide and oligoribonucleoside segments is prepared.
  • the chimeric compound has methylenecarbonylaimino linkages in both "wings" and phosphorothioate linkages in a central "gap.”
  • Example 8 In the manner of Example 8 using the chemistry of Examples 6 and 7, a chimeric compound having both oligoribonucleotide and oligoribonucleoside segments is prepared.
  • the chimeric compound has methylenecarbonylaimino linkages in one "wing" segment, phosphorothioate linkages in a central "gap” segment and methylenecarbonylamino linkages in the other "wing” segment .
  • Example 8 Methylenemethylimino/phosphodiester/phosphorothioate chimera, e . g. [2 ' -O-Me] /MMI-PO- [2 ' -OH] /PS- [-2 ' -O- Me] /MMI-PO oligoribonucleotide/oligoribonucleoside
  • a chimeric compound having both oligoribonucleotide and oligoribonucleoside segments is prepared.
  • the chimeric compounds has alternating methylenemethylimino and phosphodiester linkages in its "wing" segments and phosphorothioate linkages in its central "gap" segment.
  • EXAMPLE 12 Chimeric "end" gapped phosphorothioate oligoribonucleotides i. "3 '-End” gapped phosphorothioate chimera, e . g. [2 ' -
  • Example 8 In the manner of Example 8 a chimeric compound having an "open gap” segment at its 3 ' terminus,” a “wing” segment at its 5' terminus and phosphorothioate linkages through out is prepared.
  • Example 8 In the manner of Example 8 a chimeric compound having an "open gap” segment at its 5' terminus,” a “wing” segment at its 3' terminus and phosphorothioate linkages through out is prepared.
  • Chimeric oligoribonucleotides with uniform backbone linkages and variable nucleoside subunits i. Chimeric 2'-0-ethyl oligoribonucleotide, e . g. , [2 ' - O-Et] /PS- [2 ' -OH] /PS- [2 ' -O-Et] /PS oligoribonucleotide
  • Example 8 In the manner of Example 8 a chimeric compound having 2 ' -0-ethyl nucleosides in its "wing” segments, 2 ' -OH nucleosides in its "gap” segment and phosphorothioate linkages throughout is prepared.
  • Example 8 In the manner of Example 8 a chimeric compound having 2 ' -O-propyl nucleosides in its "wing” segments, 2 ' -OH nucleosides in its "gap” segment and phosphorothioate linkages throughout is prepared.
  • Example 8 In the manner of Example 8 a chimeric compound having 2 '-fluoro nucleosides in its "wings" segments, 2 ' -OH nucleosides in its "gap” segment and phosphorothioate linkages throughout is prepared.
  • Example 8 a chimeric compound having 2 ' -O-methoxyethyl nucleosides in its "wings" segments, 2 ' -OH nucleosides in its "gap” segment and phosphorothioate linkages through out is prepared.
  • Example 8 a chimeric compound having 2 ' -O-methoxyethyl nucleosides in its 5 ' "wing” segment, 2 ' -OH nucleosides in its "gap” segment, 2 '-fluoro nucleosides in its 3' “wing” segment, and phosphorothioate linkages through out is prepared.
  • Example 8 In the manner of Example 8 using chemistries of Example 6, a chimeric compound having 2 ' -0-methyl nucleosides in its 5' "wing” segment, 2 ' -OH nucleosides in its "gap,” 2 ' -O-fluoro nucleosides in its 3' “wing” segment, phosphorothioate linkages in the "gap” segment and the 3 ' "wing” segment and methyl phosphonate linkages in the 5' "wing” segment is prepared.
  • Example 8 In the manner of Example 8 using chemistries of Example 6, a chimeric compound having 2 ' -O-methyl nucleosides in its 5' "wing” segment, 2 ' -OH nucleosides in its "gap,” 2 ' -O-propyl nucleosides in its 3' “wing” segment, phosphorothioate linkages in the "gap” segment, methyl phosphonate linkages in 5' "wing” segment and phosphinate linkages in the 3 ' "wing” segment is prepared.
  • Chimeric oligoribonucleotides that include surrogate nucleosides i. Morpholino nucleoside surrogate containing oligoribonucleotide, e . g. , [morpholino nucleoside surrogate] • [2 ' -OH] /PS- [morpholino nucleoside surrogate] oligoribonucleotide
  • Cyclobutyl nucleoside surrogate containing oligoribonucleotide e . g. , [cyclobutyl nucleoside surrogate] /PS- [2 ' -OH] /PS- [cyclobutyl nucleoside surrogate] /PS oligoribonucleotide
  • a chimeric compound having cyclobutyl surrogate nucleosides prepared as per the teachings of U.S. Patent 5,359,044 in its "wing" segments, 2 ' -OH nucleosides in its "gap” segment and phosphorothioate linkages through out is prepared.
  • Pyrrolidine nucleoside surrogate containing oligoribonucleotide e . g. , [pyrrolidine nucleoside surrogate] /PS- [2 ' -OH] /PS- [pyrrolidine sugar] /PS oligoribonucleotide
  • Example 8 In the manner of Example 8 in combination with the chemistry of Examples 7-b, a chimeric compound having an "open gap" at its 3' terminus" formed from 2 ' -OH nucleosides having phosphorothioate linkages and PNA surrogate nucleosides in the 5' "wing" segment, is prepared.
  • EXAMPLE 16 Chimeric oligoribonucleotides that include nucleosides having modified bases i. N-2 modified purine containing oligoribonucleotide, e . g. , [Mod-purine] /PS- [2 ' -OH] /PS- [Mod-purine] /PS oligoribonucleotide
  • N-2 modified purine containing oligoribonucleotide e . g. , [Mod-purine] /PS- [2 ' -OH] /PS- [Mod-purine] /PS oligoribonucleotide
  • a chimeric compound having 4 , 7, 10, 13-tetraazahexadec-l-yl guanosine nucleosides prepared as per the teachings of U.S. Patent 5,459,255 in its "wing” segments, 2 ' -OH nucleosides in its "gap” and phosphorothioate linkages
  • Example 8 a chimeric compound having 5-propynyl pyrimidine nucleosides prepared as per the teachings of U.S. Patent 5,484,908 in its "wing” segments, 2 ' -OH nucleosides in its "gap” segment and phosphorothioate linkages through out is prepared.
  • Example 8 a chimeric compound having 6-hydroxy-2 -fluoro purine nucleosides prepared as per the teachings of U.S. Patent 5,459,255 in its "wing” segments, 2 ' -OH nucleosides in its "gap” and phosphorothioate linkages through out is prepared.
  • Example 8 a chimeric compound having 2 ' -O-propyl -5-methyl cytidine nucleosides in its "wing” segments, 2 ' -OH nucleosides in its "gap” segment and phosphorothioate linkages through out is prepared.
  • oligoribonucleotide e.g., [2 ' -O-propyl-Mod- pyr]/PS-[2'-OH]/PS-[2'-0-propyl-Mod-pyr]/PS oligoribonucleotide
  • Example 8 a chimeric compound having 2 ' -0-propyl-2-thio-5-methyl uridine nucleosides in its "wing” segments, 2 ' -OH nucleosides in its "gap” segment and phosphorothioate linkages through out is prepared.
  • Example 8 a chimeric compound having 2 ' -0-aminopropyl-2-thio-5-methyl uridine nucleosides in its "wing” segments, 2 ' -OH nucleosides in its "gap” segment and phosphorothioate linkages through out is prepared.
  • Example 8 a chimeric compound having 2 ' -O-fluoro-2-thio-5-methyl uridine nucleosides in its "wing” segments, 2 ' -OH nucleosides in its "gap” segment and phosphorothioate linkages through out is prepared.
  • T24 cells were maintained as monolayers in McCoys medium (GIBCO-BRL, Gaithersburg, MD) supplemented with 10% fetal bovine serum and 100 units/ml penicillin. After treatment with oligomeric compounds for 24 hrs the cells were trypsinzed, centrifuged and total cellular RNA was isolated according to standard protocols (see Ausubel et al . , Current Protocols in Molecular Biology, 1988, Wiley and Sons, New York, NY) .
  • RNA (10 ug) was transferred by northern blotting onto Bio-Rad Zeta probe membrane (Bio-Rad, Hercules, CA) and UV crosslinked (StratalinkerTM, Stratagene, LaJolla, CA) .
  • Membrane bound RNA was hybridized to a 32 P labeled 0.9 kb Ha-ras cDNA probe (Oncogene Science, Pasadena, CA) and exposure to XAR film (Kodak, Rochester, N.Y.). The relative amount of Ha-ras signal was determined by normalizing the Ha-ras signal to that obtained when the same membrane was stripped and hybridized with a probe for human glyceraldehyde 3-phosphate dehydrogenase (G3PDH, Clontech, Palo Alto, CA) . Signals from northern blots were quantified using phosphoimager and image quant software (Molecular Dynamics, Sunnyvale, CA) .
  • Opti-MEM Opti-MEM (GIBCO-BRL) medium containing Lipofectin (GIBCO-BRL) at a concentration of 5 ug/ml per 200nM of oligo with a maximum concentration of 15 ug/ml was added. Oligomeric compounds were added and incubated at 37°C for 4 hrs when the medium was replaced with full serum medium. After 24 hrs in the presence of the compound the cells were harvested and RNA prepared for further analysis .
  • RNase H analysis was performed using 17 base oligoribonucleotides corresponding to bases (+23 to +47) of activated (codon 12 mutation) Ha -ras mRNA. 5' End labeled RNA (20 nM) was incubated with a 100-fold molar excess of the various test oligoribonucleotides in a reaction containing 20 mM Tris-Cl, pH 7.5, 100 mM KC1, 10 mM MgCL , 1 mM dithiothreitol , and 4 units of RNase inhibitor (Pharmacia, Newark, NJ) in a final volume of 100 ⁇ l .
  • the oligoribonucleotides were melted by heating to 95°C for 5 minutes then allowed to cool slowly to room temperature in 2 liters bath of water 90°C. Duplex formation was confirmed by the shift in mobility between the single stranded end labeled sense RNA and the annealed duplex on non-denaturing polyacrylamide gels. The resulting duplexes were tested as substrates for digestion by E. coli RNase H (USB, Cleveland, OH) .
  • Duplexes used in the cell free T24 extract experiments were annealed as described above with the exception that after formation of the duplex, the reaction was treated with 1 ⁇ l of a mixture RNase T and A (Ambion RPAII kit, Austin, TX) and incubated for 15 min at 37°C, and then gel purified from a nondenaturing 12% polyacrylamide gel. T24 cell nuclear and cytosolic fractions were isolated as described previously (Szyf , M. , Bozovic, V., and Tanigawa, G. , J " . Biol . Chem. , 1991, 266, 10027-10030) .
  • Non-labeled duplex was treated with T24 extracts as done previously, half of this reaction was treated with calf intestinal phosphatase (CIP, Stratagene) and half was left untreated.
  • CIP calf intestinal phosphatase
  • the phosphatase was o inactivated by heating to 95 C and the reactions were extracted with phenol/chloroform and then precipitated in ethanol with glycogen as a carrier.
  • the precipitates were then treated with T4 polynucleotide kinase (Stratagene) and 32 P- ⁇ -ATP (ICN, Irvine, CA) .
  • the samples were again extracted by phenol/chloroform and precipitated with ethanol, the products of the reaction were then resolved on a 12% acrylamide gel and visualized by exposure to XAR film.
  • the 3 ' -terminus of the cleaved duplex was evaluated by the reaction of duplex digestion products with T4 RNA ligase (Stratagene) and 32 P-p
  • duplexes When hybridized to their cellular target the resultant duplex consists of two stretches that are not targets for nucleolytic degradation (the 2 '-methoxy "wings") and one 2'- hydroxyl oligoribonucleotide stretch that was found to be a target for a novel ribonuclease activity that recognizes RNA:RNA duplexes.
  • T24 human bladder carcinoma cells were used that contain an activating G- T transversion mutation in the Ha ⁇ ras gene at the codon 12 position. The "gapped" chimeric compounds specific for this mutation were transfected into T24 cells growing in culture.
  • T24 cells treated with RNA gapmer oligonucleotides containing 5, 7 and 9 ribonucleotides in the gap as well as a full phosphorothioate oligoribonucleotide molecule all displayed dose dependent reductions in Ha-ras steady state mRNA levels ( Figures 3B-3D) .
  • T24 cells treated with a control 9 RNA gapmer oligonucleotide that contained four mismatched bases in its sequence did not show dose dependent reduction in Ha-ras mRNA suggesting that hybridization to the target RNA is essential for activity (Figure 3E) .
  • the RNA gapmer compounds showed dose dependent inhibition of Ha-ras steady state mRNA levels .
  • RNA gapmer compounds The ability of the RNA gapmer compounds to reduce Ha -ras mRNA was dependent on the size of the RNA gap and thus the size of the RNA:RNA duplex formed in vivo .
  • Treatment of cells with the 3 base RNA gapmer compounds resulted in no cleavage of the target whereas the 5 , 7 and 9 base RNA gapmer compounds resulted in reduction in Ha -ras mRNA ( Figure 4) .
  • the fact that the RNA gapmer oligonucleotide containing 3 ribonucleotides in the gap was unable to induce reduction in target mRNA suggests that the activity involved requires a minimal RNA: RNA duplex region of at least four ribonucleotides for binding and cleavage of the target.
  • chimeric DNA gapmer oligonucleotides that contain deoxynucleotides in the gap instead of ribonucleotides show the same minimal gap size requirements to form substrates for RNase H mediated degradation of the target mRNA (Crooke et al . , Annu . Rev. Pharmacol . , 1996, 36, 107), suggesting that RNase H and the double stranded RNase activity described here may share some properties, although their substrates are clearly different.
  • a control 9 RNA gapmer compound that contains four mismatched bases in its sequence resulted in essentially no reduction in Ha-ras mRNA as expected as is shown in Figure 3E.
  • a full phosphorothioate oligoribonucleotide molecule had approximately the same activity as the 5 RNA gapmer oligo ( Figure 3D) . This might have been due to the relative decrease in stability of the full oligoribonucleotide in vivo resulting from inactivation by single stranded ribonucleases, as 2 '-methoxy phosphorothioate oligodeoxynucleotides are considerably more stable than phosphorothioate oligoribonucleotides. Crooke et al . , J. Pharmacol Exp . Ther. , 1996, 277, 923-937.
  • T24 cells with the various oligonucleotides and various concentrations up to 800nM were done in triplicate and quantification of Ha-ras mRNA levels indicate that at 600nM the 5 gapmer reduces Ha -ras mRNA by 51%, the 7 gapmer by 49%, the 9 gapmer by 77% and the full ribonucleotide by 38% when compared to non treated controls. This suggests that RNA gapmer oligoribonucleotides protected by 2 ' -methoxy wings would be more potent molecules. As shown in this example, an endoribonuclease activity in T24 human bladder carcinoma cells recognizes the internal RNA:oligoribonucleotide portion of a chimeric duplex and reduced the target mRNA levels.
  • T24 cellular extracts were prepared and tested for the ability to cleave the 9 gap oligoribonucleotide : RNA duplex in vi tro .
  • the 9 gap compound: 32 P-end labeled RNA duplex was incubated with 3 ⁇ g of cytosolic extract at 37°C for varying time periods as shown in Figure 4, followed by phenol chloroform extraction ethanol precipitation and separation of the products on a denaturing gel. That this duplex was a substrate for digestion by an activity present in T24 extracts is shown by the loss of full length end labeled RNA and the appearance of lower molecular weight digestion products indicated by arrows in Figure 4.
  • RNA portion of the duplex molecule As indicated by the sizes of the cleavage products it produces (see the physical map of the 32 P- end labeled RNA, far right in Figure 4.
  • RNase H cleavage of a 9 deoxynucleotide gap oligonucleotide :RNA duplex and cleavage of the 9 ribonucleotide gap oligoribonucleotide : RNA duplex by T24 cellular extracts appears to result in similar digestion products. This is seen by comparing the gels of Figures 4 and 5.
  • Nuclear extracts were prepared from T24 cells and tested for the ability to digest the 9 RNA gapmer oligonucleotide :RNA duplex. Nuclear extracts prepared from T24 cells were able to degrade the target duplex, and the activity was found to be present in the nuclear fraction at comparable levels to that in the cytoplasmic fractions.
  • RNA gapmer oligonucleotide was synthesized that contained phosphorothioate linkages throughout the entire length of the molecule. Since this results in increased stability to single stranded nucleases, it was reasoned that it would inhibit cleavage of the antisense strand by the dsRNase as well. Therefore, to determine if the activity described above can cleave both strands in a RNA duplex molecule, a 9 RNA gapmer antisense oligonucleotide that contained phosphorothioate linkages in the wings between the 2' methoxy nucleotides but had phosphodiester linkages between the nine ribonucleotides in the gap was synthesized.
  • a duplex composed of this 32 P-labeled 9 RNA gapmer phosphodiester/phosphorothioate oligonucleotide and its complementary oligoribonucleotide was tested as a substrate for double stranded RNase activity in T24 extracts.
  • the activity was capable of cleaving the antisense strand of this duplex as well as the sense strand and the pattern of the digestion products indicated that cleavage was again restricted to the RNA: RNA phosphodiester portion of the duplex.
  • RNA Gapmer oligonucleotide:RNA duplex is not a substrate for RNase H
  • RNA duplex was not a substrate for RNase H cleavage as no lower molecular weight bands appeared when it was treated with RNase H.
  • RNA duplex was cleaved by RNase H under the same conditions, as is evident by the appearance of lower molecular species in the enzyme treated lane ( Figure 5, left panel) .
  • a duplex composed of a 9 gapmer DNA oligonucleotide and its complementary RNA was a substrate for RNase H cleavage.
  • the fact that the RNase H cleavage sites in this particular duplex were localized to the DNA:RNA portions of the duplex further demonstrates that the RNA gapmer oligoribonucleotide : RNA duplex is not a substrate for RNase H digestion.
  • RNA-like gapmer oligonucleotides targeted to the c-Raf mRNA were not able to induce reduction in mRNA whereas RNase H active oligodeoxynucleotides targeted to the same site were able to reduce target mRNA levels.
  • RNA-like gapmer supported cleavage of the ras target RNA almost as efficiently as the "DNA gapmer.”
  • SEQ ID NO: 8 only one of the “RNA-like gapmers” targeted to c-Raf segments (SEQ ID NO: 8) supported any cleavage and the rate of cleavage for the "RNA-like gapmer” was much slower than the comparable "DNA-like gapmer.”
  • the dsRNase displays considerable sequence specificity.
  • non-labeled duplex was incubated with T24 cellular extracts as previously described then reacted with T4 polynucleotide kinase and [ 32 P ⁇ 7-ATP] with or without prior treatment with calf intestinal phosphatase.
  • Phosphatase treatment of the duplex products was seen to be essential for the incorporation of 32 P label during the reaction with polynucleotide kinase, indicating the presence of a phosphate group at the 5' termini.
  • the 3' termini were evaluated by the reaction of duplex digestion products with T4 RNA ligase and 32 P-pCp.
  • T4 RNA ligase requires a free 3 '-hydroxyl terminus for the ligation of 32 P-pCp.
  • the ability of the duplex digestion products to incorporate 32 P-pCp by T4 RNA ligase indicates the presence of 3 ' -hydroxyl groups .
  • the "sense" strand was an oligoribonucleotide having phosphodiester linkages in an eight-base gap with flanks having either (a) residues with phosphorothioate linkages or (b) 2 ' -methoxynucleosides with phosphorothioate linkages.
  • the "antisense" strand in both substrates contained 2 -methoxy phosphorothioate wings on either side of an eight-base ribonucleotide - gap having either phosphodiester or phosphorothioate linkages (Table 1) .
  • Such dsRNase substrates were more stable to exonuclease digestion than an oligoribonucleotide and substrates with both phosphorothioate linkages and 2'-methoxy nucleosides was extremely stable.
  • Emboldened- residues indicate 2 ' -methoxynucleotide residues in the "antisense" strands.
  • rat liver was homogenized in Buffer X [10 mM Hepes (ph 7.5), 25 mM KCl , 0.15 mM spermine, 0.5 mM spermidine, 1 mM EDTA, 2 M sucrose, 10% glycerol; all reagents from Sigma Chemical Co., St. Louis, MO] and centrifuged in a Beckman J2-21M centrifuge (Beckman, Fullerton, CA) at 10,000 rpm for 1.5 hours. The supernatant was precipitated with 40% ammonium sulfate (Sigma) .
  • dsRNase activity was recovered in the 40% ammonium sulfate precipitate.
  • the pellet was resuspended in Buffer A [20 mM Hepes (ph 6.5), 5 mM EDTA, 1 mM DTT, 0.25 mM phenylmethylsulfonyl fluoride (PMSF) , 0.1 M KCl, 5% glycerol, 0.1% NP40, 0.1% Triton X-100; all reagents from Sigma] and dialyzed to remove ammonium sulfate. Approximately 40 g of cytosolic extract were obtained from 0.5 kg liver.
  • the homogenate was centrifuged in a J2-21M centrifuge (Beckman) at 10,000 rpm for 1.5 hrs. The supernatant was precipitated with 70% ammonium sulfate.
  • the pellet was resuspended in Buffer A and dialyzed. All the dsRNase activity was recovered in the 70% ammonium sulfate precipitate. Approximately 5 g Of nuclear extract were obtained from 0.5 kg liver.
  • Ion exchange chromatography was then performed in order to further purify the dsRNases of the invention.
  • Nuclear and cytosolic extracts in Buffer A were loaded onto Hi-Trap columns (Pharmacia, Piscataway, NJ) for FPLC.
  • the extracts were eluted with a linear gradient of NaCl and samples were collected. The UV absorption at 257 77M of the samples was determined.
  • Samples were centrifuged at 8,000 g for 10 minutes, resuspended in Buffer A, concentrated in Ultrafree-15 centrifugal filter devices (Millipore, Bedford, MA) and analyzed for activity.
  • the dsRNase activity eluted in fractions corresponding 300-450 mM NaCl.
  • the dsRNase activity in the nuclear extract eluted at 700- 800 mM NaCl.
  • Fractions from the ion exchange chromatography were concentrated and subjected to size exclusion chromatography. Active samples from the ion exchange chromatography were pooled, applied to a TSK G-3000 column (TosoHaas, Mongomeryville, PA) and run with Buffer A containing 100 mM NaCl. Samples (200 to 400 ⁇ l) were collected and their UV absorption at 257 nM was determined. Samples were concentrated using Ultrafree-15 centrifugal filter devices (Millipore) and then analyzed for activity.
  • Figure 6 shows a polyacrylamide gel electrophoretic analysis of the concentrated active fractions after the ion-exchange chromatography, and the fractions from the size exclusion chromatography.
  • the fraction with greatest dsRNase activity (lane 4, Figure 6) had a molecular weight range of about 50 to about 80 kilodaltons, and a band at approximately 50 kilodaltons appeared to be enhanced on 12 % polyacrylamide gel electrophoresis (PAGE) performed using precast gels (Novex, San Diego, CA) .
  • Table 2 provides a summary of the purification and recovery of dsRNase activities from nuclear and cytosolic liver extracts.
  • One unit is defined as the amount of sample required to digest 10 fMol dsRNA duplex in 15 minutes at 37°C under the conditions described herein.
  • dsRNase activity from liver nucleii and cytosol suggests that at least two dsRNases with differing properties are capable of cleaving double- strand RNA.
  • the nuclear dsRNase eluted at higher NaCl concentrations from the ion exchange column than the cytosolic dsRNase.
  • both require Mg ++ and cleave at several sites within the oligoribonucleotide gap.
  • duplex substrate Both require a duplex substrate and can cleave oligoribonucleotides in a duplex that is made up of oligoribonucleotide "sense” and a 2' methoxy phosphorothioate chimeric "antisense” strand when the duplex has phosphorothioate or phosphorothioate-2' methoxy nucleoside wings.
  • the dsRNases are further purified by a variety of means.
  • the use of organic solvents is avoided as the dsRNases of the invention are unstable in acetonitrile or methanol (see below) , and the assays described herein are used to evaluate the presence or absence of the desired dsRNase in a sample.
  • Further purification steps may include, but are not limited to, the following means.
  • Sepharose columns have been utilized in the purification of a sequence-specific ribonuclease from Rana catesbeiana (bullfrog) oocytes (Liao, Nucl . Acids Res . , 1992, 20 , 1371) , a ribonuclease from Xenopus laevis oocytes (Nitta et al . , Biol . Pharm . Bull . (Jpn .
  • Hydrophobic interaction chromatography is a powerful protein purification means which depends on strong salting-out salts to increase the hydrophobic interactions between the desired protein and a ligand therefor (Narhi et al . , Anal . Biochem. , 1989, 182, 266).
  • Hydrophobic interaction columns have been used to purify ribonuclease A from undesired contaminants (Wu et al . , Methods in Enzymology, 1996, 270, 27; Wetlaufer et al . , J. Chromatography, 1986, 359, 55).
  • the dsRNases of the invention may also be further purified by hydroxyapatite chromatography (Kennedy, Methods in Enzymology, 1990, 282, 339) . Endo- and exo- ribonuclease have been purified from Trypanosoma brucei using hydroxyapatite chromatography (Gbenle, Exp . Parisi tol . , 1990, 71 , 432; Gbenle, Mol . Biochem . Parasi tol . , 1985, 15, 37). RNA affinity columns may also be used to further purify the dsRNases of the invention.
  • RNA affinity column (Pharmacia, Piscataway, NJ) may be used.
  • a column is prepared in which the matrix thereof comprises one or more of the dsRNase substrates of the invention (for details, see the following Example) . Due to the relative sequence specificity of the dsRNase of the present invention, the latter type of affinity column may be preferable.
  • samples comprising the dsRNases of the invention are treated in such a manner so as to limit the degradative capacity of the dsRNase without significantly altering its ability to bind to the double- stranded RNA substrate of the matrix.
  • the degradative activity of the dsRNase of the invention is inhibited in solutions lacking available Mg ++ due to, for example, the addition of appropriate chelating agents such as EDTA, or by addition of NaCl to a sample containing such dsRNases to a final concentration of at least 300 mM (see the following subsection) .
  • EXAMPLE 27-C Characterization of purified mammalian dsRNases The effects of various conditions on the dsRNase activity were evaluated using the active fractions after ion exchange chromatography.
  • the dsRNase activity was demonstrable in Tris or phosphate buffers from about pH 7 to about pH 10.
  • the dsRNase activity was not stable in solution in acetonitrile or methanol.
  • the activity was inhibited by NaCl; dsRNase activity was inhibited by 30% at 10 mM NaCl, >60% at 100 mM NaCl and 100% at 300 mM NaCl. Heating for five minutes at 60°C, 80°C or 100°C, inactivated the dsRNase.
  • Optimum activity was seen in the temperature range of about 37°C to about 42°C. At 25°C, the dsRNase activity was approximately 50% of that observed at 37°C. The dsRNase activity was inhibited at 10, 20 and 50 mM EDTA, but not at 5 mM, in agreement with its requirement for Mg ++ , and was stable to multiple freeze/thaws.
  • the sense oligonucleotide was 5 ' -end labeled with 32 P using [g 32 P]ATP, T4 polynucleotide kinase, and standard procedures (Ausubel et al . , 1989).
  • the labeled oligonucleotide was purified by electrophoresis on 12% denaturing PAGE (Sambrook et al . , 1989).
  • the specific activity of the labeled oligonucleotide was approximately 5000 cpm/fmol.
  • Oligonucleotide duplexes were prepared in 30uL reaction buffer [20 mM tris-HCl (pH 7.5), 20 mM KCl, 10 mM MgCl 2 , 0.1 mM DTT] containing 10 nM antisense oligonucleotide and 10 5 cpm 32 P labeled sense oligonucleotide. Reactions were heated at 90° C for 5 min and incubated at 37° C for 2 h.
  • the oligonucleotide duplexes were incubated in either unpurified and semipurified cellular extracts at a total protein concentration of 75 ug unpurified cytosolic extract, 60 ug unpurified nuclear extract, 5 ug ion exchange purified cytosolic fraction, 5 ug ion exchange purified nuclear fraction, or 0.5 ug ion exchange and gel filtration purified nuclear fraction. Digestion reactions were incubated at 37° C for 0-240 min. Following incubation, 10 uL of each reaction was removed and quenched by addition of denaturing gel loading buffer [5 uL 8 M urea, 0.25% xylene cyanole FF, 0.25% bromphenol blue] .
  • the reactions were heated at 95° C for 5 min and resolved in a 12% denaturing polyacrylamide gel. The remaining aliquot was quenched in 2 uL native gel loading buffer [glycerol, 0.25% xylene cyanole FF. The reactions were resolved at 10° C in a 12% native polyacrylamide gel containing 44 mM Tris-borate and 1 mM MgCl 2 . Gels were analyzed using a Molecular Dynamics Phosphorimager .
  • Figure 7 displays the native gel results.
  • Lane 1 shows the position at which the untreated 32 P-labeled sense strand migrated in the native gel
  • lane 2 shows "sense" strand RNA treated with 0.02 units RNase VI.
  • Figure 8 shows the results of analysis of products of digestion of dsRNAse substrates by denaturing polyacrylamide gel electrophoresis. Lane 1 shows
  • Lane 10 is an RNA base hydrolysis ladder included for sizing purpose.
  • nucleic acid affinity columns comprise a matrix comprising a nucleic acid substrate for a desired compound that binds the substrate either nonspecifically or in a sequence- specific manner.
  • RNA affinity columns have also been employed to purify RNA-binding proteins and ribonucleases (see, e.g., Prokipcak et al . , J. Biol . Chem . , 1994, 269 , 9261; Dake et al . , J. Biol.
  • a matrix comprising one or more dsRNase substrates of the invention has the advantage of providing a dsRNA substrate that is resistant to the action of single-stranded ribonuclease which are prevalent in many tissues and cells.
  • Such a matrix also comprises a suitable solid support and a linker that provides a bridge between the solid support and the dsRNase substrate (s) .
  • Suitable solid supports include, but are not limited to, graft polymers (U.S. Patent No. 4,908,405 to Bayer and Rapp) ; polyacrylamide (Fahy et al., Nucl . Acids Res., 1993, 22, 1819); polyacrylmorpholide, polystyrene and derivatized polystyrene resins (Syvanen et al., Nucl. Acids Res., 1988, 16, 11327; U.S. Patent Nos. 4,373,071 and 4,401,796 to Itakura), including amino methyl styrene resins (U.S. Patent No.
  • linker a variety of chemical linking groups or chains may be employed in the matrices of the invention. Any chemical group or chain capable of forming a chemical linkage between the solid support and the dsRNase substrate may be employed.
  • a suitable linker has the preferred characteristic of non-reactivity with compounds introduced during the various steps of oligonucleotide synthesis. It will be appreciated by those skilled in the art that the chemical composition of the solid support and the dsRNase substrate will influence the choice of the linker.
  • Many suitable linkers will comprise a primary amine group at either or both termini, as many chemical reactions are known in the art for linking primary amine groups to a variety of other chemical groups; however, other terminal reactive moieties are known and may be used in the invention.
  • Suitable linkers include, but are not limited to, linkers having a terminal thiol group for introducing a disulfide linkages to the solid support (Day et al . , Biochem. J. , 1991, 278, 735; Zuckermann et al . , Nucl. Acids Res., 15, 5305) ; linkers having a terminal bromoacetyl group for introducing a thiol-bromoacetyl linkage to the solid support (Fahy et al . , Nucl.
  • an n-aminoalkyl chain is the linker.
  • RNA synthesis chemistry is based on the selective incorporation of various protecting groups at strategic intermediary reactions.
  • a useful class of protecting groups includes silyl ethers.
  • bulky silyl ethers are used to protect the 5 '-hydroxyl in combination with an acid-labile orthoester protecting group on the 2 '-hydroxyl .
  • This set of protecting groups is then used with standard solid-phase synthesis technology. It is important to lastly remove the acid labile orthoester protecting group after all other synthetic steps.
  • the early use of the silyl protecting groups during synthesis ensures facile removal when desired, without undesired deprotection of 2' hydroxyl.
  • RNA oligonucleotides were synthesized.
  • RNA oligonucleotides are synthesized in a stepwise fashion. Each nucleotide is added sequentially (3'- to 5 '-direction) to a solid support-bound oligonucleotide. The first nucleoside at the 3 '-end of the chain is covalently attached to a solid support. The nucleotide precursor, a ribonucleoside phosphoramidite, and activator are added, coupling the second base onto the 5 '-end of the first nucleoside. The support is washed and any unreacted 5'-hydroxyl groups are capped with acetic anhydride to yield 5'-acetyl moieties.
  • the linkage is then oxidized to the more stable and ultimately desired P (V) linkage.
  • the 5 '-silyl group is cleaved with fluoride. The cycle is repeated for each subsequent nucleotide.
  • the methyl protecting groups on the phosphates are cleaved in 30 minutes utilizing 1 M disodium-2 -carbamoyl-2 -cyanoethylene-1, 1-dithiolate trihydrate (S 2 Na 2 ) in DMF.
  • the deprotection solution is washed from the solid support-bound oligonucleotide using water.
  • the support is then treated with 40% methylamine in water for 10 minutes at 55°C. This releases the RNA oligonucleotides into solution, deprotects the exocyclic amines, and modifies the 2'- groups.
  • the oligonucleotides can be analyzed by anion exchange HPLC at this stage.
  • the 2 '-orthoester groups are the last protecting groups to be removed.
  • the ethylene glycol monoacetate orthoester protecting group developed by Dharmacon Research, Inc. (Lafayette, CO), is one example of a useful orthoester protecting group which, has the following important properties. It is stable to the conditions of nucleoside phosphoramidite synthesis and oligonucleotide synthesis. However, after oligonucleotide synthesis the oligonucleotide is treated with methylamine which not only cleaves the oligonucleotide from the solid support but also removes the acetyl groups from the orthoesters .
  • the resulting 2 -ethyl-hydroxyl substituents on the orthoester are less electron withdrawing than the acetylated precursor.
  • the modified orthoester becomes more labile to acid-catalyzed hydrolysis. Specifically, the rate of cleavage is approximately 10 times faster after the acetyl groups are removed. Therefore, this orthoester possesses sufficient stability in order to be compatible with oligonucleotide synthesis and yet, when subsequently modified, permits deprotection to be carried out under relatively mild aqueous conditions compatible with' the final RNA oligonucleotide product. Additionally, methods of RNA synthesis are well known in the art (Scaringe, S. A. Ph.D.
  • RNA antisense compounds of the present invention can be synthesized by the methods herein or purchased from Dharmacon Research, Inc (Lafayette, CO) . Once synthesized, complementary RNA antisense compounds can then be annealed by methods known in the art to form double stranded (duplexed) antisense compounds.
  • duplexes can be formed by combining 30 ⁇ l of each of the complementary strands of RNA oligonucleotides (50 ⁇ M RNA oligonucleotide solution) and 15 ⁇ l of 5X annealing buffer (100 mM potassium acetate, 30 mM HEPES-KOH pH 7.4, 2 mM magnesium acetate) followed by heating for 1 minute at 90°C, then 1 hour at 37°C.
  • 5X annealing buffer 100 mM potassium acetate, 30 mM HEPES-KOH pH 7.4, 2 mM magnesium acetate
  • Duplex RNAs may be designed to one or more target RNAs .
  • the nucleobase sequence of the antisense strand of the duplex may be identical to the 18 nucleobase target sequence with one additional complementary base on the 3' end of the oligoribonucleotides followed by a two-nucleobase overhang of deoxythymidine (T) , TT.
  • T deoxythymidine
  • the sense strand of the dsRNA is designed and synthesized as the complement of the antisense strand and also contains the two-nucleobase overhang on the 3' end making both strands of the dsRNA duplex complementary over the central 19 nucleobases and each having a two- base overhang on the 3' end.
  • each RNA oligonucleotide is aliquoted and diluted to a concentration of 50 ⁇ M. Once diluted, 30 ⁇ L of each strand is combined with 15 ⁇ L of a 5X solution of annealing buffer. The final concentration of said buffer is 100 mM potassium acetate, 30 mM HEPES-KOH pH 7.4, and 2mM magnesium acetate. The final volume is 75 ⁇ L. This solution is incubated for 1 minute at 90°C and then centrifuged for 15 seconds. The tube is allowed to sit for 1 hour at 37°C at which time the dsRNA duplexes can be used in experimentation. The final concentration of the dsRNA duplex is 20 ⁇ M. This solution can be stored frozen (-20°C) and freeze- thawed up to 5 times.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés oligomères comprenant des oligoribonucléotides et des oligoribonucléosides ayant des sous-séquences de 2'-pentoribofurane-osyl nucléosides activant dsRNase. Les oligoribonucléotides et les oligoribonucléosides peuvent contenir des groupes de substitution afin d'augmenter l'affinité de liaison avec des brins d'acides nucléiques complémentaires et d'augmenter la résistance de la nucléase. Les composés oligomères sont utilisés à des fins de diagnostic et d'autres recherches, pour moduler l'expression d'une protéine dans des organismes et pour le diagnostic, la détection et le traitement d'autres pathologies se prêtant à un traitement oligonucléotidique. Font également l'objet de cette invention des ribonucléases de mammifère, notamment des enzymes dégradant l'ARN et des substrats pour de telles ribonucléases. Une telle ribonucléase fait également l'objet de cette invention sous forme de dsRNase, 'ds' indiquant la spécificité de la RNase pour certains substrats d'ARN à double brin. Les substrats artificiels pour les dsRNases de cette invention servent à la préparation de matrices d'affinité pour purifier une ribonucléase de mammifère ainsi que des protéines de liaison d'ARN non dégradantes.
PCT/US2003/009808 2003-03-31 2003-03-31 Oligoribonucleotides et ribonucleases de clivage d'arn Ceased WO2004097049A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2003220608A AU2003220608A1 (en) 2003-03-31 2003-03-31 Oligoribonucleotides and ribonucleases for cleaving rna
EP03716922A EP1611249A4 (fr) 2003-03-31 2003-03-31 Oligoribonucleotides et ribonucleases de clivage d'arn
PCT/US2003/009808 WO2004097049A1 (fr) 2003-03-31 2003-03-31 Oligoribonucleotides et ribonucleases de clivage d'arn

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2003/009808 WO2004097049A1 (fr) 2003-03-31 2003-03-31 Oligoribonucleotides et ribonucleases de clivage d'arn

Publications (1)

Publication Number Publication Date
WO2004097049A1 true WO2004097049A1 (fr) 2004-11-11

Family

ID=33415178

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/009808 Ceased WO2004097049A1 (fr) 2003-03-31 2003-03-31 Oligoribonucleotides et ribonucleases de clivage d'arn

Country Status (3)

Country Link
EP (1) EP1611249A4 (fr)
AU (1) AU2003220608A1 (fr)
WO (1) WO2004097049A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7432249B2 (en) 1996-06-06 2008-10-07 Isis Pharmaceuticals, Inc. Oligoribonucleotides and ribonucleases for cleaving RNA
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8604183B2 (en) 2002-11-05 2013-12-10 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
CN106366145A (zh) * 2015-07-25 2017-02-01 成都博腾药业有限公司 一种(2’r)-2’-脱氧-2’-氟-2’-甲基脲苷的制备方法
WO2019023459A1 (fr) 2017-07-28 2019-01-31 Bristol-Myers Squibb Company Dinucléotides cycliques utilisés en tant qu'agents anticancéreux
WO2019122282A1 (fr) * 2017-12-22 2019-06-27 Roche Innovation Center Copenhagen A/S Oligonucléotides gapmères comprenant une liaison internucléosidique phosphorodithioate
CN112500446A (zh) * 2020-12-11 2021-03-16 平江县吉成科技有限责任公司 一种2’-氟-2’-脱氧尿苷的合成方法
CN114621303A (zh) * 2022-03-01 2022-06-14 思合基因(北京)生物科技有限公司 一种高效的2′-o-取代核苷的制备方法
KR102893739B1 (ko) 2023-04-14 2025-12-01 파미셀 주식회사 대용량 고순도의 2’-디옥시-2’-플루오로우리딘의 제조 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107094A (en) * 1996-06-06 2000-08-22 Isis Pharmaceuticals, Inc. Oligoribonucleotides and ribonucleases for cleaving RNA

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL145778A0 (en) * 1999-04-21 2002-07-25 American Home Prod Methods and compositions for inhibiting the function of polynucleotide sequences
DE10100588A1 (de) * 2001-01-09 2002-07-18 Ribopharma Ag Verfahren zur Hemmung der Expression eines Zielgens

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107094A (en) * 1996-06-06 2000-08-22 Isis Pharmaceuticals, Inc. Oligoribonucleotides and ribonucleases for cleaving RNA

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP1611249A4 *
STRUCK M.: "Vaccine R&D success rates and development times", NATURE BIOTECHNOLOGY, vol. 14, May 1996 (1996-05-01), pages 591 - 593 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7432249B2 (en) 1996-06-06 2008-10-07 Isis Pharmaceuticals, Inc. Oligoribonucleotides and ribonucleases for cleaving RNA
US7695902B2 (en) 1996-06-06 2010-04-13 Isis Pharmaceuticals, Inc. Oligoribonucleotides and ribonucleases for cleaving RNA
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US8604183B2 (en) 2002-11-05 2013-12-10 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
CN106366145A (zh) * 2015-07-25 2017-02-01 成都博腾药业有限公司 一种(2’r)-2’-脱氧-2’-氟-2’-甲基脲苷的制备方法
WO2019023459A1 (fr) 2017-07-28 2019-01-31 Bristol-Myers Squibb Company Dinucléotides cycliques utilisés en tant qu'agents anticancéreux
WO2019122282A1 (fr) * 2017-12-22 2019-06-27 Roche Innovation Center Copenhagen A/S Oligonucléotides gapmères comprenant une liaison internucléosidique phosphorodithioate
EP4092117A1 (fr) * 2017-12-22 2022-11-23 Roche Innovation Center Copenhagen A/S Oligonucléotides gapmer comprenant une liaison internucléoside phosphorodithioate
CN112500446A (zh) * 2020-12-11 2021-03-16 平江县吉成科技有限责任公司 一种2’-氟-2’-脱氧尿苷的合成方法
CN114621303A (zh) * 2022-03-01 2022-06-14 思合基因(北京)生物科技有限公司 一种高效的2′-o-取代核苷的制备方法
CN114621303B (zh) * 2022-03-01 2024-04-02 思合基因(北京)生物科技有限公司 一种高效的2′-o-取代核苷的制备方法
KR102893739B1 (ko) 2023-04-14 2025-12-01 파미셀 주식회사 대용량 고순도의 2’-디옥시-2’-플루오로우리딘의 제조 방법

Also Published As

Publication number Publication date
AU2003220608A1 (en) 2004-11-23
EP1611249A4 (fr) 2006-06-28
EP1611249A1 (fr) 2006-01-04

Similar Documents

Publication Publication Date Title
EP0928290B1 (fr) Oligoribonucleotides et ribonucleases pour cliver l'arn
US6043352A (en) 2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides
AU762212C (en) Oligonucleotides having A-DNA form and B-DNA form conformational geometry
WO2000006590A1 (fr) Oligonucleotides 2'-modifies de ciblage de l'arn preorganises de maniere conformationnelle
AU2003228477B2 (en) Oligomeric compounds having modified phosphate groups
JP2002531574A (ja) 細胞接着分子の腫瘍壊死因子α−誘導発現のモジュレート方法
WO2001023613A1 (fr) Rnase h humaine et compositions nucleotidiques correspondantes
EP1117672A1 (fr) Modulation anti-sens de l'expression de la survivine
JP2003521913A (ja) Ｓｕｒｖｉｖｉｎ発現のアンチセンスモジュレーション
EP1611249A1 (fr) Oligoribonucleotides et ribonucleases de clivage d'arn
JP2002526095A (ja) 腫瘍壊死因子受容体関連因子（ｔｒａｆ）の発現のアンチセンスモジュレーション
US6020198A (en) Antisense modulation of RIP-1 expression
AU2003205017B2 (en) Antisense modulation of survivin expression
JP2002519015A (ja) Ｔｎｆｒ１発現のアンチセンスモジュレーション

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003716922

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003716922

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003716922

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP